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Summary 
General purpose and objectives 
Foot-and-mouth disease (FMD) is a viral infection of implicit financial importance for 
countries, such as Denmark, which rely on a significant trade in agricultural products. The 
disease is highly contagious with rapid spread amongst susceptible animals, causing 
substantial economical implications for farmers and live-stock industries of affected 
countries. The occurrence of persistently infected, so called “carriers” of FMD-virus (FMDV) 
which may shed infectious virus for prolonged periods of time following exposure to the 
virus, causes significant complications for effective disease control. 
The main purpose of this PhD-project has been to investigate the host response to FMD 
infection in cattle, with further objectives of elucidating any detectable differences in the 
measured immune response between animals that developed into FMDV carriers and those 
that did not. 
Experimental studies 
The thesis is based on results obtained from seven separate animal experiments with FMDV 
serotype O, which have been performed at DTU-Vet, Lindholm. In five out of the six 
experiments that were performed in cattle, animals were infected with FMDV O UKG 
34/2001, representing the virus isolate responsible for the FMD outbreak in the UK and 
northern Europe in 2001. One cattle experiment was performed with an FMDV serotype O 
isolated from samples collected from a cattle farm in Uganda during an outbreak in 2006, 
whilst one additional experiment was designed to investigate the clinical course of infection 
with FMDV O UKG 34/2001 in sheep. 
An experimental study design involving endoscopical collection of small biopsies of 
pharyngeal mucosa from live cattle was developed. This technique enables collection of 
sequential tissue samples from infected animals, allowing investigation of the local tissue 
response to infection within this specific anatomical region of individual animals, at different 
time points following infection. 
This sampling system was used to investigate the pathogenesis of FMD infection in cattle 
through quantification of the levels of FMDV RNA present within the pharyngeal epithelia 
during early infection. Similar analyses were performed on samples of pharyngeal epithelia 
Summary 
 
6 
 
and associated lymph nodes collected during post mortem examinations performed at around 
32-35 days post infection in order to investigate possible sites of virus persistence. 
The early host response to FMDV O in cattle was investigated through measurements of 
systemic parameters consisting of the acute phase proteins, serum amyloid A (SAA) and 
haptoglobin (HP), as well as type 1 interferon (IFN). The local tissue response within the 
pharyngeal epithelia was investigated through measurements of mRNA levels of 
inflammatory cytokines in sequential biopsy samples.  
Structure of Thesis 
The first chapter contains general background information on the host response to virus 
infections, as well as characteristics of FMDV and the pathogenesis of the infection. Detailed 
aims and objectives of the project are stated at the end of chapter 1.  
Chapter 2 contains overall descriptions of the animal experiments included in the project. The 
general concepts of the experimental procedures are described, as well as the clinical 
characteristics of infection caused by the two different FMDV O isolates in cattle. The 
clinical description of the experiment performed with FMDV O UKG 34/2001 in sheep 
includes results of measurements of viremia and the development of specific anti-FMDV O 
antibodies, as these results are not presented in the included manuscripts. 
The third chapter of the thesis contains three manuscripts of research articles for publication 
in peer-reviewed scientific journals.  
The first manuscript is based on serological measurements of the acute phase proteins SAA 
and HP, together with the bioactivity of type 1 IFN, in three out of the performed cattle 
experiments. Measurements of the systemic response to early infection with FMDV is related 
to the observed development of clinical signs of infection as well as the occurrence of 
viremia and development of anti-FMDV antibodies. Observed variations in the acute phase 
response of HP between carriers and non-carriers are discussed. 
The second manuscript contains results from measurements of mRNA levels of inflammatory 
cytokines IFNα- and –β as well as tumor necrosis factor –α (TNF-α), in collected biopsy 
samples. The type 1 interferon response in the analyzed tissue samples is discussed in relation 
to the previously reported systemic interferon response. The measured cytokine responses, as 
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well as an observed variation in the TNF-α response between carriers and non-carriers, are 
discussed in relation to previous publications within the subject area. 
The third manuscript deals with investigations of possible sites of virus replication during 
early and persistent phases of infection. Levels of FMDV RNA was quantified in sequential 
biopsy samples of pharyngeal mucosa harvested during early infection, as well as in 
corresponding tissue samples collected post mortem. 
The final chapter of the thesis contains a general discussion of the obtained results, together 
with overall conclusions and future perspectives for continued research within the specific 
area. 
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Resumé 
Formål 
Mund-og-klovesyge (MKS) er en virusinfektion af meget stor økonomisk betydning for 
lande, der lige som Danmark, er afhængige af en betydelig eksport af animalske produkter fra 
landbruget.  Sygdommen er ekstremt smitsom, og spredes hurtigt fra dyr til dyr. Persistent 
inficerede dyr (”carriers”) er i stand til at udskille levende virus i lang tid, uden at vise 
kliniske tegn på sygdom, hvilket gør det meget vanskeligt at kontrollere sygdommen når den 
bliver introduceret i et sygdomsfrit område. 
Hovedformålet med dette PhD-projekt har været at undersøge værtsresponsen ved infektion 
med MKS virus (MKSV) serotype O i kvæg, med fokus på at udforske eventuelle faktorer i 
værtsdyrenes respons, der kunne være relateret til udvikling af ”carriers”. 
Eksperimentelle studier 
Denne afhandling er baseret på resultater fra syv dyreforsøg med MKSV serotype O, udført 
ved DTU-Vet, Lindholm.  
I fem ud af seks forsøg udført i kalve, er dyrene blevet inficeret med MKSV O UKG 
34/2001, hvilket er den virusstamme der forårsagede et omfattende udbrud af MKS i England 
og Nord Europa i 2001. Et kalveforsøg blev udført med en MKS serotype O virus isoleret fra 
en kvægfarm i Uganda i forbindelse med et MKS udbrud i 2006. Et yderligere forsøg blev 
udført for at undersøge den kliniske infektion i får med den Britiske virusstamme (O UKG 
34/2001). 
Der blev udviklet en forsøgsmodel, hvor små vævsprøver (biopsier) blev udtaget fra den 
pharyngeale slimhinde fra levende kalve ved hjælp af endoskopi. Denne teknik muliggør 
udtagelse af gentagne vævsprøver fra de inficerede dyr, hvilket gør det muligt at følge det 
lokale immunrespons, i det enkelte dyr, igennem forskellige stadier af infektionen.  
Denne nyudviklede forsøgsteknik blev brugt til at undersøge patogenesen af MKS-infektion i 
kalve gennem målinger af MKSV RNA i det pharyngeale epithel i de tidlige faser af 
infektionen. Den mulige lokalisering af det persisterende virus blev undersøgt ved tilsvarende 
analyse af vævsprøver fra det pharyngeale epithel, samt tilhørende lymfeknuder, der blev 
udtaget ved obduktion. 
Resumé 
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Det akutte værtsrespons ved infektion med MKSV O i kvæg blev undersøgt ved målinger af 
systemiske markører bestående af akut fase proteinerne serum amyloid A (SAA) og 
haptoglobin (HP) samt type 1 interferon (IFN). Det lokale inflammatoriske respons i det 
pharyngeale epithel blev undersøgt ved kvantificering af mRNA niveauer af inflammatoriske 
cytokiner i gentagne biopsiprøver. 
Afhandlingens struktur 
Det første kapitel inkluderer generel information om værtsresponset ved virusinfektioner, 
samt karakteristika af MKSV og patogenesen ved MKS infektionen. Projektets detaljerede 
formål er angivet sidst i kapitel 1. 
Kapitel 2 indeholder beskrivelser af de dyreforsøg der er blevet udført i projektet. Udover 
generel information om det udviklede forsøgs-design samt anvendte metoder, er der 
beskrivelser af de observerede kliniske sygdomstegn ved infektion med de to forskellige 
MKSV O isolater der blev brugt i kvægforsøgene. Beskrivelsen af forsøget med MKSV O 
UKG 34/2001 i får, inkluderer, udover kliniske sygdomsbeskrivelser også resultater fra 
målinger af viræmi og antistof-respons, da disse data ikke er præsenteret i de inkluderede 
videnskabelige manuskripter. 
Det tredje kapitel indeholder tre manuskripter udarbejdet for publikation i videnskabelige 
tidsskrifter. 
Det første manuskript er baseret på målinger af akut fase proteiner SAA og HP, samt 
bioaktiviteten af type 1 IFN i sera fra tre af de udførte kvægforsøg. Målinger af det 
systemiske akut fase- og cytokin respons tidligt i infektionen sammenholdes med opståen af 
specifikke kliniske sygdomstegn, samt udvikling af viræmi og antistof-respons. En observeret 
forskel i HP respons, mellem carriers og ikke-carriers bliver, endvidere diskuteret. 
Det andet manuskript indeholder resultater af målinger af mRNA niveauer af de 
inflammatoriske cytokiner IFN-α og –β, samt tumor necrosis faktor –α (TNF-α)  i de udtagne 
biopsiprøver. Det tidlige respons af type 1 IFN i det lokale væv bliver diskuteret i forhold til 
det tidligere publicerede systemiske IFN respons. Det målte cytokinrespons i vævet, samt en 
observeret forskel i TNF-α respons mellem carriers og ikke-carriers bliver diskuteret i forhold 
til tidligere publikationer indenfor det specifikke område. 
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Det tredje manuskript omhandler den mulige lokalisering af virus replikation i de tidlige, 
samt persistente faser af MKSV infektion i kvæg. Niveauer af MKSV RNA bliver 
kvantificeret i biopsier fra pharynx, udtaget i de tidlige faser af infektionen, samt i tilsvarende 
vævsprøver udtaget ved obduktion af dyr i den persistente fase. 
Afhandlingens afsluttende kapitel indeholder en generel diskussion af de opnåede resultater, 
samt konklusioner, og muligheder og perspektiv for fremtidlige studier indenfor det aktuelle 
emne. 
Chapter 1.                                                                                       Introduction  
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1. Introduction 
Background. 
Foot-and-mouth disease (FMD) is an economically devastating viral infection which affects 
cloven-hoofed animals including cattle, pigs and sheep. The disease is highly contagious, 
spreading rapidly amongst susceptible animals, with vast financial implications for farmers 
and agricultural industries of affected countries. 
FMD is endemic in large parts of the world, including major parts of South America, Africa, 
the middle-east and Asia.  Most developed countries, including the EU, USA and Australia, 
are kept free of FMD by means of restrictions on trade and strict controls on import of 
agricultural products from endemic areas. An outbreak of the disease in normally disease free 
areas can   result in huge consequences for the agricultural industry due to export bans and 
limitations of trade. As an example of this, the direct costs for handling of the outbreak of 
FMD in the UK in 2001 have been estimated to have reached £2,75 billion, whilst indirect 
costs in the form of combined losses related to agricultural export and the tourist trade are 
believed to amount to an additional £5,75 billion
6
.     
The general strategy for controlling FMD outbreaks in disease free areas is based on a 
“stamping out”-policy, with culling of all infected and susceptible animals within an area 
surrounding the affected farms. Furthermore, larger restriction zones with bans on transport 
and trade of animals and animal products, including transport of animals destined for 
slaughter, are maintained for prolonged periods. The stamping-out strategies imply huge 
demands on control agencies in the form of logistics and financial resources. In addition to 
this, the ethical dimension related to the destruction of vast numbers of both infected and 
healthy animals gives rise to considerable public debate.  
It is possible to vaccinate animals against FMD, indeed the huge number of outbreaks that 
occurred in Europe in the 1950/60’s were controlled through this approach. Furthermore, 
during recent years the application of emergency vaccination has proven to be an effective 
measure in order to control dissemination of FMD during outbreaks
36
. However, protective 
immunity acquired from available FMD-vaccines will only last for up to six months, and 
vaccination strategies are further complicated by the fact that there are seven different 
serotypes of the virus, with little or no cross-protection between serotypes.   
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Characteristics of the clinical FMDV infection 
The characteristic clinical picture of FMD infection in cattle involves a transient increase in 
body temperature accompanied by the typical clinical signs of lameness, excessive salivation 
and inappetence. Vesicular lesions develop in areas covered by cornified stratified squamous 
epithelia such as the oral cavity and coronary bands. Infected animals develop a significant 
viremia, with high levels of FMDV detectable in the blood for about 2-3 days. The viremia is 
effectively counteracted by the development of high titres of specific neutralizing antibodies 
within 4-7 days following the appearance of clinical disease.  
Disease severity varies greatly between different virus isolates, as well as between different 
host species
2
. Mortality rates are generally very low in adult animals, whereas juvenile 
animals may develop fatal myocarditis as a consequence of the infection. The clinical course 
of the disease is usually over within 14 days after infection, but the occurrence of persistently 
infected, so called “carrier-animals” within ruminant species causes further complications for 
disease control. 
 
Host response to virus infections 
The host immune system functions to protect the individual against infectious disease by 
means of recognizing the presence of potentially harmful agents within the body and 
eliminating these through the actions of highly regulated effector mechanisms. Subsequent 
immunological memory is generated in order to enable a stronger and more efficient immune 
response upon repeated exposure to a specific pathogen. 
The Innate Immune Response 
The innate immune response is the first line of host defense. This branch of the immune 
system acts in a non-specific manner in order to eliminate any substance or agent not 
belonging to the body itself. Microorganisms that cross the epithelial barriers of the skin or 
the mucosa of the gut or respiratory tract are likely to be detected by phagocytic cells present 
in the submucosa
55
. Macrophages are mature phagocytes of the monocyte lineage that 
recognize common features present on several classes of pathogens through the action of 
pattern recognizing surface receptors (PRRs). Encountered pathogens are internalized leading 
to destruction of the pathogen itself, as well as the production of signaling molecules in the 
Chapter 1.                                                                                       Introduction  
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form of inflammatory cytokines which function to activate and recruit other effector cells of 
the immune system
55
. Macrophages are also involved in “clearing up” the debris from 
damaged cells as well as removal of inactivated pathogens which have been neutralized by 
other branches of the immune response. 
Another class of phagocytes are the granulocytes, or polymorphonuclear leukocytes, which 
include neutrophils, eosinophils and basophils. These cells are mainly involved in the defense 
against bacterial and parasitic infections, and their functions will therefore not be discussed in 
further detail. 
The third class of phagocytic cells is constituted by the dendritic cells (DC). Immature cells 
of the DC lineage migrate through the bloodstream from the bone marrow to enter various 
tissues of the body. DCs take up particulate matter that they encounter and display peptide 
fragments of these, bound to major histocompatibility (MHC) complexes on the cell surface. 
DCs are stimulated through activation of PRRs or by the action of the inflammatory 
cytokines secreted by macrophages leading to further secretion of cytokines by the DCs 
themselves, as well as the expression of co-stimulatory molecules on the cell surface
29,57
. 
Activated DCs act as antigen-presenting cells (APCs) with the main function of activating 
immature T- lymphocytes through presentation of specific antigens bound to cell-surface 
MHC-complexes. DCs thereby constitute a crucial link between the functions of the innate 
host response and the subsequently initiated adaptive immune response
54
. Plasmacytoid DCs 
belong to a specific lineage of DC which in addition to functioning as APCs also have an 
adjunct role in modifying the immune response through the production of large amounts of 
type 1 interferons (IFNs) in response to viral infection
54
.  
The Adaptive Immune Response 
The initial actions of the innate immune response are soon followed by the induced adaptive 
response. The adaptive immune response acts through clonal expansion of lymphoid cells 
expressing surface receptors capable of high affinity binding to specific pathogens that are 
encountered
54
.  
T- and B-lymphocytes are produced in the central lymphoid tissues within the thymus and 
bone marrow respectively. Immature lymphocytes migrate to peripheral lymphoid organs 
such as the spleen and lymph nodes following a stringent process of clonal deletion of any 
cells expressing receptors with potentially self-reactive binding capacities. The specificity of 
the variable region displayed on surface receptors of B- and T-lymphocytes is randomly 
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generated through serial events of gene rearrangement during generation of the lymphocyte 
precursors
53
. Each lymphocyte displays numerous copies of receptors of identical specificity 
on their surface. Immature lymphocytes will only become effective after activation through 
interaction with an APC presenting antigen matching the receptor binding site together with 
necessary co-stimulatory molecules. 
APC displaying bound antigen migrate to peripheral lymphoid organs upon stimulation by 
inflammatory cytokines and the activation of PRRs. Immature lymphocytes with receptor 
specificity matching the presented antigens are selected for clonal expansion leading to the 
subsequent generation of a large number of activated B- and T-cells expressing receptors 
with specific binding capacities
56,57
. 
The surface receptors of activated B-lymphocytes are secreted as specific antibodies 
(immunoglobulins) as the B-cells develop into mature plasma cells. The main function of 
secreted antibodies is to neutralize pathogens through the generation of immune complexes 
consisting of pathogens bound by several antibody molecules. Immune complexes of 
opsonized pathogens are subsequently removed by phagocytes
56
. This specific mechanism of 
clearing infections by the adaptive immune response is of high importance in viral infections, 
as will be discussed in more detail further on. 
There are several subsets of mature T-lymphocytes with varying functions within the 
adaptive immune response. T-cells are commonly divided into subsets with similar functions 
as defined by the expression of different surface molecules. CD8
+
 T-lymphocytes are 
cytotoxic cells that are capable of killing virus infected cells following interaction with 
antigens displayed by MHC class I on the surface of infected cells. This class of T-cells is 
therefore generally considered to be of high importance for the host response to viral 
infections
57
.  
CD4
+
 T-cells are also known as helper T-cells (TH-cells), and can be further subdivided into 
TH1 and TH2-cells as well as the more recently discovered TH17 and regulatory T-cells. TH1 
and TH2 cells are important for the activation of antibody production and subsequent class 
shifting in B-lymphocytes. TH1 and TH2 cells induce production of immunoglobulins of 
different isotypes and the nature of the T-cell response will therefore have a direct effect on 
the antibody response. TH1 cells are also involved in providing activating signals to cytotoxic 
T-cell subsets, as well as interacting with MHC class II complexes expressed by macrophages 
in order to induce destruction of ingested pathogens
57
. 
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The development of the different subsets of CD4
+
 T-cells is directed by the mixture of 
inflammatory cytokines produced by cells of the innate immune system, most importantly by 
the DCs, which will favour the induction of either a TH1 or a TH2-cell response. A 
predominating TH1 response will induce a cellular response through activation of cytotoxic 
CD8
+
 T-cells, as well as the production of opsonizing antibodies of IgG isotype. TH2-cells 
will instead promote humoral immunity through induction of IgM, IgA and IgE. Although 
both subsets of helper T-cells are usually induced during the acute phase of infection, one or 
the other of the TH1 and TH2 subsets is often found to predominate in infections that become 
chronic
57
. 
Another type of lymphocyte displaying cytotoxic activity are the natural killer (NK) cells. 
NK cells function as a feature of the innate immune response as they do not express surface 
receptors of specific binding capacities such as other lymphocytes, but are instead activated 
to kill any cell displaying epitopes detected as “non-self” 43. 
Cytokines and other InflammatoryMarkers of specific interest 
Type 1 Interferons 
IFNs are a family of cytokines which have been named according to their ability to interfere 
with the replication of intracellular pathogens. There are several sub-classes of IFNs; type 1 
IFNs include the predominant types IFN-α and –β, whilst type II IFN is constituted by IFN-γ. 
Type I IFNs are induced through signaling pathways involving activation of nuclear 
transcription factor кB (NF-кB) through either one of two complementary receptor systems65. 
The first pathway of activation is through a class of ubiquitously expressed cytosolic 
receptors that detect viral nucleic acids in infected cells. These receptors are functional in 
almost all types of nucleated cells with the function of inducing type I IFN in response to 
viral infections. The second class of receptors is the Toll-like receptors (TLRs) which belong 
to a germline-encoded family of PRRs that has evolved to detect molecular features shared by 
entire classes of pathogens
29
. Of high importance in viral infections are TLR-3 and-7 that are 
located within endosomes of specialized cells, such as DCs, and which are activated upon 
detection of double- and single stranded RNA respectively
29,65,72
. As these TLRs are located 
in the membranes within intracellular compartments of phagocytic cells, this pathway of IFN 
induction does not require that the cell itself is actively infected by the virus. The restricted 
distribution of TLR-3 and-7 to intracellular compartments will provide access to material 
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internalized by the phagocytic cells, and at the same time prevent self-recognition as the 
binding sites of the receptors are kept isolated from the cytosol.  
Type I IFNs interact with a common cell surface receptor leading to transcription of several 
kinds of IFN- inducible gene products, all with the common function of protecting the 
stimulated cell against virus infection. As examples of this, the IFN induced 2’-5’ 
oligoadenylate synthases (OAS) functions to activate the nuclease RNAse L, leading to 
degradation of viral RNA, whilst the Mx proteins have proven to be effective in protecting 
cells against influenza and vesicular stomatitis virus
65
. 
Type 1 IFNs induce expression of co-stimulatory molecules necessary for activation of 
lymphocytes by macrophages and DCs
55
, and have been shown to facilitate cross presentation 
of viral antigens to cytotoxic CD8
+
 T-cells by DCs
46
. The cytotoxic activity of CD8
+
 T-
lymphocytes is further enhanced by the induction of an increased expression of cell-surface 
MHC class I on IFN stimulated cells
47,55
. It has furthermore been shown that cells stimulated 
by type 1 IFN become sensitized to undergo apoptosis upon subsequent viral infection
64
 
whilst IFN also functions to directly stimulate cytotoxic activity in Natural Killer (NK) 
cells
65
. These functions may serve important roles in limiting the spread of infection as virus 
infected cells will be rapidly eliminated. 
Interferon-γ 
IFN-γ is an important cytokine produced by mature T-lymphocytes and NK cells. This 
cytokine has various regulatory functions associated with the adaptive immune response. It 
serves as a highly potent activator of macrophages and stimulates antigen presentation 
through both MHC class I and II
16
. IFN-γ acts through a cell-surface receptor which is 
distinct from the type 1 IFN-receptor
65
. The downstream effects of IFN-γ involve a general 
modulation of the immune response through stimulation and repression of a large number of 
genes associated with cytokine production as well as events related to cellular proliferation 
and apoptosis
16
. The expression of IFN-γ is in itself regulated through interactions with other 
cytokines such as IFN-α and-β and tumor necrosis factor (TNF)-α16. 
Tumor necrosis factor-α 
Tumor necrosis factor--α (TNF-α) is a common pro- inflammatory cytokine which is secreted 
by cells of the innate immune system in response to various kinds of infectious agents and 
tissue damage. It functions by stimulating a local inflammatory reaction in order to contain 
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the infection and by stimulating the recruitment of a large number of immune cells
55
. The 
local inflammatory reaction serves to modulate expression of surface molecules on 
endothelial cells while increasing the permeability of small blood vessels in order for cells of 
the immune system to gain access to the site of infection. Similar functions make TNF-α a 
highly potent actor in the pathogenesis of septic shock. A systemic release of this cytokine in 
response to a pathogen present within the bloodstream will cause general vasodilation with 
subsequent loss of blood pressure and multiple organ failure. The importance of TNF-α in the 
host response to viral infections has been investigated in relation to its possible involvement 
in control and potential reactivation of latent virus infections
22,44
. 
The Acute Phase Proteins 
A characteristic property of the inflammatory cytokines induced during the innate immune 
response is induction of what is known as the acute phase response which involves a shift in 
proteins synthesized and secreted by the liver. The acute phase proteins (APPs) constitute a 
broad family of proteins whose serum levels are either up- or down regulated in response to 
infection. Some of the APPs have distinct functions in the host response to infection. C-
reactive protein and mannose binding lectin are important APPs in humans and are capable of 
opsonizing pathogens by binding to certain molecular features found on the surface of 
various pathogens
55
. Other APPs have less well defined functions but may serve as easily 
measurable markers indicative of the presence of a systemic response to inflammation or 
other kinds of physical stress or trauma
11,61
. 
The value of different APPs as markers of disease is different between different host 
species
40
. In cattle, serum amyloid A (SAA) and haptoglobin (HP) have proven to be reliable 
markers that are significantly induced in many types of both bacterial and viral 
infections
33,39,40
. HP is a protein that binds free hemoglobin in the circulation. It is present at 
very low concentrations in serum of healthy cattle, but there can be a several thousand-fold 
increase within a few days in response to infection
32
. SAA is a precursor of amyloid A 
protein. It is present at measurable levels in healthy cattle, but will react by a very rapid up-
regulation upon acute inflammation and can be found at levels of approximately 5 to 10 times 
the normal serum concentrations in acutely infected animals
32
. 
Both the innate and adaptive immune responses are highly important when discussing the 
host response to FMD. The virus has developed several strategies of circumventing the 
immune system
34,62
 in order to evolve into an effective and extremely contagious pathogen. 
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Further knowledge of the mechanisms of interaction between FMDV and the different 
functions of the host immune system may be useful when developing strategies for 
prevention and control of the disease. 
 
Foot-and-mouth disease in cattle 
The virus 
FMD-virus (FMDV) exists in seven distinct serotypes; O, A, C, Asia-1 and South African 
Territories (SAT) 1, 2 and 3, with a large number of subtypes within each serotype
45
. It is a 
non-enveloped, positive stranded RNA virus belonging to the Aphthovirus genus of the 
picornavirus family. The virus capsid consists of 60 copies each of four structural proteins; 
VP1, VP2, VP3 and VP4
13
. The main function of the capsid is protection of the RNA genome 
as well as attachment to host cell surface receptors. Within live animals, the interaction with 
cells is achieved primarily through binding to αv integrin receptors, most importantly αvβ3 
and αvβ658,67. Following attachment to host cells the viral genome is delivered to the 
cytoplasm where viral replication takes place, after which subsequent release of viral progeny 
occurs through complete lysis of the host cell. 
The viral genome consists of a single copy of infectious RNA (approximately 8,5 kb in 
length), and contains a single large open reading frame encoding a polyprotein which is 
cleaved, via multiple intermediates, by virus  encoded proteases during and following 
translation. 
Figure 1: Organization of the FMDV genome. 
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The 5’-terminal region of the FMDV genome contains an extensive untranslated region 
(UTR) of more than 1300 nucleotides. This part of the genome is essential for FMDV 
replication and pathogenesis as it includes an internal ribosomal entry site (IRES) which 
enables translation of the viral RNA even though all cap-dependent translation of host cell 
mRNA is blocked in infected cells
14
 
Host cell protein synthesis is efficiently shut off by the action of the FMDV leader protease 
(Lpro), which is a papain-like cystein protease located at the N-terminus of the polyprotein 
(Figure 1). The Lpro has the function of inducing the cleavage of the translation initiation 
factor eIF4G, following its self-cleavage from the growing polyprotein during translation of 
the FMDV genome
13
. As FMDV initiates translation in a cap-independent fashion through 
the action of the IRES, the virus is not dependent on intact eIF4G for translation, and can thus 
freely make use of the host cell machinery for protein synthesis
14,48
. 
The assembled capsid proteins constitute the sites of antigenic recognition, and also facilitate 
attachment and entry of virus to the host cells.  Genetic variations in the regions encoding 
these proteins are therefore important determinants of FMDV characteristics. 
The proteins encoded in the P2 and P3 regions of the FMDV genome are nonstructural 
proteins involved in replication of the viral genome as well as processing and assembly of the 
structural viral proteins. The 3C protease (3Cpro) acts on the majority of cleavage sites 
within the FMDV polyprotein and has also been shown to be capable of cleavage of several 
proteins involved in host cell protein synthesis
15
. The 3D protein is the virus encoded RNA-
dependent RNA polymerase, which is highly conserved between different sero- and subtypes 
of FMDV. During FMDV replication the 3D protein initially transcribes a negative strand 
copy of the RNA genome, which is then used as template for the transcription of new copies 
of the positive strand genome. 
 FMDV pathogenesis 
FMDV pathogenesis has been studied in detail by several research groups. The initial site of 
FMDV replication has been suggested to be located within epithelia and lymphoid associated 
tissues of the pharyngeal area
3,6,21,51,59
 or, alternatively, within the lungs
18,19
.  
An experimental study of the early pathogenesis of FMDV in cattle performed by Pacheco et 
al
59
 showed that FMDV RNA could be isolated from tissue samples from both the upper and 
lower respiratory tracts at 24 hours post aerosol exposure to FMDV serotype O. Infectious 
FMDV could be isolated from tissue samples collected from the upper respiratory tract at a 
Chapter 1.                                                                                       Introduction  
 
20 
 
significantly higher level than from similar samples derived from the lower respiratory tract, 
although samples from both sites were positive for FMDV genome by qRT-PCR. It was 
proposed that FMDV would reach the lower respiratory tract following aerosol exposure but 
that the pulmonary tissues were only poorly permissive to FMDV replication whilst primary 
virus replication was found within respiratory-associated lymphoid tissues of the upper 
airways
59
. In a subsequent publication, the same group went on to define the initial site of 
virus replication as being located within the epithelial cells overlying the lymphoid crypts of 
the pharyngeal mucosa. It was concluded that substantial viral replication took place within 
pulmonary cells of epithelial histiogenesis as early as 6 hours post aerosol exposure, with a 
decrease in viral load in pharyngeal tissues detected at 48 hours post exposure
8
. It was thus, 
proposed that the early pathogenesis of FMD in cattle involves primary replication in 
pharyngeal epithelia during the “pre-viremic” phase of infection, with the highest viral load 
found within the epithelia of the dorsal soft palate (DSP). It was further concluded that there 
is a subsequent widespread FMDV replication within pulmonary pneumocysts which is 
accompanied by a significant decrease in viral load within pharyngeal tissues
8
. 
In contrast to these recent findings, previous work of other authors have failed to find 
supportive evidence for FMDV replication within the lungs
6,21
. Burrows et al performed an 
extensive study of the pathogenesis of FMDV in cattle in 1981
21
. Results from this study 
were based on investigations of sites of viral replication through isolation of infectious virus 
from tissue samples collected from 56 cattle that had been subjected to varying routes of 
FMDV exposure. It was concluded that large amounts of live virus could be isolated from the 
pharyngeal region, whereas there was little or no evidence of FMDV replication within the 
lower respiratory tract
21
. These findings are also in line with what have been concluded by 
other research groups in subsequent studies. Zhang and Alexandersen measured the RNA-
loads in different tissues during acute and persistent stages of FMDV infection in cattle
75
. It 
was in this study proposed that the initial phase of viral replication took place within the 
pharyngeal epithelia, whilst substantial viral amplification was found within vesicular lesions 
in the epithelia of the oral cavity and coronary bands. It was possible to detect FMDV RNA 
in the lungs of viremic animals, but at levels that were much lower than what was found at 
sites of secondary viral replication, and thus, the lungs were not considered  to play an 
important role in the pathogenesis of FMDV in cattle
75
. 
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Thus, there is still no clear consensus regarding the early pathogenesis of FMD, and 
comparison of published results is confounded by variations in experimental design with the 
use of different virus strains and varying routes of initial administration of the virus. 
Following primary replication, the virus spreads systemically via the lymphatics and vascular 
system to the peripheral sites of secondary replication which are characterized by the 
presence of stratified cornified squamous epithelia, such as the coronary bands and oral 
cavity
3
. Infected cattle develop transient viremia lasting for about 2-3 days, which is 
counteracted by the development of circulating anti-FMDV antibodies. Clearance of viremia 
is achieved by the action of phagocytic cells, most importantly macrophages, which are 
effective in detecting and internalizing opsonized FMDV
49
.  
As indicated above, the clinical disease follows a rapid time course and is typically 
manifested by a sudden rise in body temperature and development of vesicular lesions at 
peripheral areas of viral replication. The degrees of salivation, inappetence and lameness 
observed in affected animals may vary in correlation to the severity of lesions. In animals 
housed under normal conditions of modern farming facilities, ruptured vesicles often become 
the site of bacterial infections. These secondary infections may have severe implications for 
the welfare and usability of dairy cattle as a result of chronic injuries to the feet and udders. 
The viral infection in itself may also have a direct effect on the milk yield of infected cattle, 
as well as on growth rates and the overall welfare and ability to withstand other infections in 
all animals affected. These long-term effects of FMDV infection are of high relevance to 
areas of the world where the disease is endemic and infected animals are not culled. 
In the absence of secondary bacterial infections at the sites of FMDV lesions, the clinical 
course of the infection usually subsides within 7-14 days, although ruminants may develop 
into persistently infected “carrier-animals”. 
FMDV carriers  
FMDV carriers are defined as animals with asymptomatic, intermittent, presence of 
infectious virus in oropharyngeal fluid beyobd 28 days after infection
62
. It is believed that in 
these animals (approximately 50% of infected cattle), FMDV is capable of persisting, at a 
low level of replication within pharyngeal epithelial cells
20,80
, or as intact, but largely 
quiescent, viral particles within germinal centers in pharyngeal tissues
42
. These animals are a 
source of infectious virus, and their presence is therefore unacceptable in areas free of FMD. 
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The carrier state can develop in animals which have been immunologically naïve at the time 
of exposure to the virus, as well as in animals that are protected against the clinical disease by 
the presence of adequate levels of circulating antibodies due to vaccination or previous 
exposure to the virus
20,30,62
.  The duration of the carrier state varies between species, with the 
longest duration recorded in African buffaloes (5 years), followed by cattle (2 years) and 
sheep (9 months)
25,50,52,66
.  Pigs do not become carriers of FMDV
5
.  
FMDV carriers have high titres of circulating anti-FMDV-antibodies, and as viral excretion 
may be intermittent and of a low level, it may be difficult to detect carriers by screening of 
animals at herd level. As a direct consequence of this, according to current regulations in 
areas kept free of FMDV without vaccination, any animal with anti-FMDV antibodies in the 
circulation is a potential carrier of the virus, and is thus, not accepted. These circumstances 
have profound implications for the control measures applied in order to handle FMDV 
outbreaks in disease free areas. Although emergency vaccination has proven to be an 
effective measure to prevent spread of FMDV
36
, all animals that have been vaccinated against 
FMD will subsequently have to be eliminated in order for the country to regain a completely 
FMD-free status, with fully lifted restrictions on international trade. 
Host response to FMDV 
As previously discussed, viral infections of the respiratory tract are usually sensed by effector 
cells of the innate immune system, such as mature cells of the monocyte lineage, which are 
present in the respiratory mucosa. Activation of pattern recognizing cellular receptors leads to 
production of an array of pro-inflammatory cytokines, such as tumor necrosis factor–α (TNF-
α) and type 1 IFN. 
Recent studies have demonstrated that the Lpro of FMDV is capable of down-regulation of 
transcription of IFN-β through interaction with NFκB27,73. Clinical experiments with an 
attenuated FMDV mutant lacking the Lpro have indicated a decrease in the ability of this 
virus to spread from the initial site of replication compared to the corresponding wild-type 
strain
17,19
. It has been proposed that the decreased pathogenicity of this leaderless mutant may 
be a direct consequence of the virus’s inability to block host cell IFN expression, which 
would normally leave neighboring cells more resistant to virus infection
17
.   
 
It has been shown that uptake of FMDV by macrophages is possible without the aid of 
opsonizing antibodies, although the phagocytic activity of these cells becomes much efficient 
as a result of the interactions of cellular Fc receptors with virus bound immunoglobulins
49
.  
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In contrast to this, cell culture based experiments have demonstrated a necessity for FMDV to 
be bound by specific antibody in order to induce transcription of IFN by naturally IFN 
producing cells (NIPC) of the DC lineage
35
. This would imply that a significant release of 
IFN by plasmacytoid DCs in response to FMDV infection would not occur until the 
concentration of anti-FMDV antibodies in the circulation has reached adequate levels.  
There has been some varying reports on whether FMDV is capable of actively infecting cells 
of the DC lineage
67
. Bautista et al
12
 concluded that porcine skin DC were refractory to 
infection by FMDV, possibly due to high levels of IFN-α expression. It has also been 
reported that other lineages of DCs are susceptible to FMDV infection, albeit resulting in an 
abortive infection, which does not lead to cytopathic effects or subsequent release of viral 
progeny
37
. Regardless of the possible mechanisms of cellular uptake and infection, 
production of type 1 IFN seems to be an important consequence of the interaction between 
FMDV and DCs
12,35,67
.  
FMDV replication in cell culture is highly sensitive to the inhibitory effects of type 1 IFNs
24
 
and it has also been demonstrated that IFN-γ is capable of clearing persistent FMDV 
infection in cultured bovine epithelial cells
81
. Other studies have demonstrated the potential 
of both IFN-α23 and IFN-γ74 to provide protection against the development of clinical disease 
in pigs challenged with FMDV. The exact mechanisms by which FMDV may interact with 
cells of the innate immune system as well as the nature of interactions between the virus and 
the hosts IFN response represent areas of research that deserve further study. 
Aspects of specific interest in FMDV immunology 
Neutralizing anti-FMDV antibodies may be detected in the circulation of infected animals as 
early as 3-4 days following natural infection. Although the immune response induced by 
FMDV is rapid, the window between antigen exposure and the development of adaptive 
immunity may be crucial when applying emergency vaccination as a control measure in the 
event of an FMD outbreak. Previous studies have demonstrated a protective immunity 
following vaccination against FMDV which preceded achievement of what has normally 
been considered as being protective levels of specific antibody in the circulation
26,30,31
.  It has 
been postulated that this early protection achieved by high potency emergency vaccines 
against FMDV may be a consequence of activation of the innate immune response
10
, with 
further suggestions of the specific involvement of a cellular response of γδ-Tcells7,69 and NK 
cells
71
.  
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FMDV has developed several mechanisms for effective evasion of the host immune 
response
34
. In addition to a general suppression of host cell protein synthesis
15,48
 and a more 
specific interference with the host cell IFN response through degradation of NFкB27, FMDV 
is also capable of  interfering with surface expression of MHC class I molecules
63
. 
Continuous expression of peptide epitopes derived from the interior of the cell by cell surface 
MHC complexes plays an important role in the cellular defense mechanisms against viral 
infections. Cytotoxic CD8
+
 T-cells are activated to kill virus infected cells upon detection of 
“non-self” peptides presented by MHC class I molecules. By preventing surface expression 
of viral antigen, FMDV is capable of circumventing this specific branch of the cellular 
immune response. However, it has also been shown that a general down regulation of MHC 
class I expression may trigger NK cell cytotoxicity
41
, and may thus mediate clearance of 
virus infected cells through this mechanism. The critical point about down regulation of 
MHC class I may be that it provides the time required for the virus to replicate and then 
spread efficiently to another host. Investigations of early cellular mechanisms involved in the 
response to FMDV infection could be useful for the development of effective emergency 
vaccines against FMD. 
Other persistent virus infections  
There are several viruses that are capable of causing persistent infections, with or without 
apparent clinical disease. Many of these viruses are tumor causing agents such as the DNA 
viruses human papilloma virus (HPV) and Epstein Barr virus (EBV), which are capable of 
persisting through interference with the proliferation and lifespan of infected cells
81
. Human 
immunodeficiency virus (HIV) and Human T-cell carcinoma virus (HTCV) have an RNA 
genome, but belong to the retrovirus family. These viruses encode an RNA-dependent DNA 
polymerase and are capable of latent persistence by incorporating a DNA copy of the viral 
genome into the host cell DNA. A virus of more relevance to the pathogenesis of FMDV 
could  be the Hepatitis C virus (HCV), a positive stranded RNA virus belonging to the 
Flavivirus family. HCV causes a persistent chronic infection in 80% of infected humans, 
whereas the remaining 20% will suffer a more acute infection, which is subsequently cleared. 
Research on HCV persistence has been focused on how the virus is capable of circumventing 
the immune system, proposing the involvement of a blunted CD8
+
 response in addition to 
interference with DC functions
38
. 
Within the veterinary field, the non cytopathic version of the bovine viral diarrhea virus 
(BVDV), another member of the Flavivirus family, is capable of causing persistent infection 
Chapter 1.                                                                                       Introduction  
 
25 
 
in fetuses that are exposed to the virus during early gestation. These animals develop an 
immunological tolerance towards the virus, and are capable of shedding large amounts of 
BVDV throughout their life time
60
. 
As FMDV is an RNA virus, it would not be expected to be capable of persisting latently 
within cells as would be the case for some more stable DNA viruses such as different 
members of the herpes virus family. The instability of the RNA genome would require 
FMDV to maintain a low level of replication in order to persist within infected cells. Whilst 
acute FMDV infection is of a highly cytolytic nature, resulting in complete destruction of 
infected cells, the virus does not cause any lesions or clinical signs of disease during 
persistent infection. The high titres of neutralizing antibodies found in the blood indicate an 
intracellular localization of the virus. How this virus is capable of persisting without being 
targeted by the cellular immune response, and which factors that are involved in determining 
if an animal will develop into a persistently infected carrier or not, remain to be elucidated. 
 
Project Aims 
It is clear that the innate immune response plays an important role in FMDV infection in 
cattle. Further investigations of the acute host response to this infection may provide 
information that could help elucidate possible mechanisms responsible for the variations in 
outcome of the clinical infection. Understanding of immunological events involved in the 
development of persistently infected subclinical carriers of FMDV may be useful in the 
development of effective intervention strategies for control and prevention of FMD 
outbreaks. 
The general aims of this project have been: 
 Development of an experimental model for FMDV in cattle that enables collection of 
tissue samples from the pharyngeal mucosa of live animals at sequential time points 
during the infection. 
 Investigation of the systemic immune response to FMDV infection through 
measurements of markers of the acute phase response  in the blood of infected 
animals. 
 Investigation of the local host response to FMDV infection by characterization of the 
expression of relevant genes in samples of pharyngeal mucosa collected at sequential 
time points during infection. 
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 Investigation of FMDV pathogenesis through analysis of the level of viral replication 
in the pharyngeal mucosa during acute and chronic stages of infection.  
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2. Clinical studies of infection with FMDV serotype O in cattle and sheep 
The contents of this thesis is based on the results of seven separately performed clinical 
experiments with FMDV serotype O. Six of the experiments were performed in cattle with 
one additional experiment investigating the clinical course of FMDV infection in sheep. One 
of the cattle experiments was performed as part of another project investigating certain 
serological aspects related to epidemiology and surveillance of FMDV in endemic areas of 
eastern Africa. In this experiment vaccinated and naïve animals were challenged with a field 
strain (FMDV O UG 312/2006) isolated from samples collected from a cattle-farm in 
Mbarara district, Uganda, during an outbreak of FMD in 2006. In all of the remaining 
experiments, the animals were inoculated with a serotype O isolate originating from the FMD 
outbreak in the UK in 2001 (FMDV O UKG 34/2001).  
 
Table 1. Overview of animal experiments included in the project.  
 
 
Experimental ID Animal 
Species 
Infected 
Animals 
(Inoculated : 
contact) 
Control 
animals  
Virus Isolate Duration of 
experiment 
(PID)  
FMD P1C 2008 Cattle 8 (4:4)  FMDV O  
UKG 34/2001 
65 
FMD 2S 2008 Sheep 20 (12:8)  FMDV O  
UKG 34/2001 
140 
FMD 3C 2008 Cattle 12 (6:6)  FMDV O  
UKG 34/2001 
100 
FMD 4C 2009 Cattle 12 (12:0)  FMDV O 
UG 312/2006 
32 
FMD 5C 2010 Cattle 12 (6:6) 3 FMDV O  
UKG 34/2001 
32 
FMD 6C 2010 Cattle 12 (6:6) 3 FMDV O   
UKG 34/2001 
14 
FMD 7C 2010 Cattle 12 (6:6) 3 FMDV O 
UKG 34 /2001 
36 
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Table 2. Alternative experimental IDs, as referred to in manuscript 1-3. 
Cattle Experiments  
The initial experiment performed as a part of this project (FMD P1C 2008) was the first 
animal experiment to be performed within the newly built BSL-3+Ag research facilities at 
DTU-Vet Lindholm. The purpose of this experiment was, apart from introducing the concepts 
of working with FMDV in the natural host species within biosecure research facilities, to 
produce a batch of virus which could be used in subsequent experiments. For this reason, four 
calves (1 inoculated and 3 contact infected) were euthanized during the acute phase of 
infection in order to harvest epithelial samples from which infectious virus could be 
harvested.  
As the definition of an FMDV carrier is an animal that excretes live virus for more than 28 
days after infection
62
, the remaining animals from the first experiment and animals of the 
following experiments were kept for observation and sampling for periods exceeding this to 
allow determination of individual animal’s carrier status. One experiment (FMD 6C 2010) 
was, however, terminated at PID 14 due to technical reasons. The duration of the individual 
experiments (see Table 1) refers to the number of days from inoculation to termination. 
Animals were generally allowed a period of approximately 14 days for acclimatization and 
sampling prior to inoculation. 
FMDV O UKG 34/2001   
FMDV O UKG 34/2001 belongs to the Middle-East South Asia (ME-SA) topotype of FMDV 
serotype O. It is a well characterized isolate, which has been utilized in several clinical 
studies of FMDV infection in both cattle, pigs and sheep
1,6,75,77
.  
Experimental ID Alternative ID 
FMD 3C 2008 FMD 2008 
FMD 5C 2010 FMD2010a 
FMD 6C 2010 FMD 2010b 
FMD 7C 2010 FMD 2010c 
Chapter 2.                                                                             Clinical Studies                                                                                 
 
29 
 
The inoculum used in the majority of the experiments included in the project (see Table 1.) 
was prepared from a virus isolate obtained from World Reference Laboratory for FMD at the 
Institute for Animal Health (IAH) Pirbright, UK. This virus was originally isolated from an 
abbatoir sample collected from a pig during the FMD outbreak in the UK in 2001. The isolate 
had been passage once in cattle at the IAH-Pirbright (from bovine VI31 17/12/04, 10
7.0 
TCID50), before being transferred to DTU-Vet, Lindholm. 
Virus Inoculum 
Prior to the first experiment, the inoculum obtained from the IAH-Pirbright was tested in 
primary bovine thyroid (BTY) cell culture in order to determine the current titre. A volume of 
10μl of the original suspension was used for titration (starting with a dilution of 1:100) 
showing a titre of 10
8.0
 TCID50/ml. A subsequent 10 fold dilution in phosphate buffer resulted 
in an estimated titre of 10
7.0
, and each of the 4 inoculated animals recieved 0.5 ml of the 
diluted inoculum, resulting in an individual dose consisting of 10
6.7
 TCID50. 
The inoculum used for subsequent experiments with FMDV O UKG 34/2001 was obtained 
through pooling of virus harvested from the tongue epithelia of two of the contact infected 
animals that were euthanized during the acute phase of infection in the first experiment. The 
titre of this batch of inoculum was determined to be 10
8.5
TCID50/ml in primary BTY cells 
following the previously described procedure. The inoculum was stored in aliquots at -20
o
C 
with added glycerol (50%) and was subsequently diluted 10-fold in phosphate buffer prior to 
administration. Each animal inoculated in subsequent experiments received 0.5 ml of the 
diluted inoculum, corresponding to a single dose of 10
6.9 
TCID50. 
Experimental Procedure 
All animals were pre-treated using a broad spectrum antibiotic (enrofloxacin; Baytril©; 2.5 
mg/kg or tetracycline; Aquacyclin® 5mg/kg) for four days upon arrival in order to treat any 
existing bacterial infection and were further treated with β-lactam penicillin (streptocillin©; 
5ml/100kg) for four days around inoculation to avoid interference caused by any bacterial 
infections. 
In all of the cattle experiments performed with FMDV O UKG 34/2001, one half of the 
animals included in the study were directly inoculated through sub-epidermal injection in the 
tongue
6
. In the experiment FMD 4C 2009, where animals were infected with a Ugandan field 
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isolate, all 12 animals included in the study were directly inoculated in the tongue. Animals 
that were not subjected to direct inoculation gained the infection through continuous contact 
with inoculated animals, with two inoculated and two contact animals in each pen, and the 
stable facilities also allowing for physical contact between animals in separate pens.  
Animals that were randomly selected for inoculation were sedated through intravenous 
injection of Xylazin (Rompun® 2%; 1 ml/100kg) before receiving the inoculum administered 
at 5-6 separate injection sites at the base of the tongue (Figure 2). Following the inoculation, 
the animals were revived through intravenous injection of atipamezol (Antisedan® vet; 0.4 
ml per ml of Rompun previously administered).  
The method of subepidermo-lingual inoculation
6
 is easily reproducible, it allows for control 
of the amount of infectious virus that each inoculated animal receives and the method has 
previously been used in numerous experimental studies of FMD in cattle
4,75,78
. Although 
representing an artificial route of viral entry, direct inoculation in the tongue may simulate 
viral entry through damaged epithelia such as could occur through abrasions present within 
the oral cavity or in the skin. It can further be argued that the animals included in the contact 
infected groups in these experiments will receive the virus under what would resemble 
natural conditions through direct transmission of virus from one animal to another.  
 
 
 
 
 
 
 
 
 
Figure 2. Sedated calf receiving FMDV inoculum through subepidermal injection in the 
tongue. 
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Collection of routine samples 
A similar protocol for routine sampling was used in all of the performed experiments. All 
animals were monitored daily, with measurements of rectal temperature and observation of 
clinical signs. Serum samples were collected daily from 3 days prior to inoculation and 
throughout the first two weeks of the experiments but then on a weekly basis throughout the 
remaining part of the experiment.   
Samples of oropharyngeal fluid (probang samples)
68
 for quantification of virus excretion 
were collected prior to inoculation, once daily during the first week after inoculation, then 
every other day throughout the second week and on a weekly basis subsequently. Additional 
probang samples were collected after PID 28 so that the carrier status of individual animals 
was based on the analysis of a minimum of four samples. The uninfected control animals 
which were included in the last three experiments performed were handled and sampled 
following a protocol similar to that used for infected animals. These animals were kept in a 
separate isolation unit and were subjected to sedation and “mock-inoculation” using 
phosphate buffer, in order to mimic the procedure used for inoculation and sample collection 
in the test groups. 
Results from quantification of viremia and development of anti-FMDV antibodies as well as 
measurements of acute phase proteins and type 1 interferon in serum are reported in 
manuscript number 1. Results from measurements of viral excretion in probang samples, as 
well as the prevalence of animals that developed into FMDV carriers are reported in 
manuscript number 3. 
Development of method for collection of biopsy samples of pharyngeal mucosa 
During the second cattle experiment (FMD 3C 2008) a novel technique for endoscopical 
collection of small tissue samples from the pharyngeal mucosa of the dorsal soft palate (DSP) 
of live animals was introduced. This experimental model was developed in order to allow 
collection of sequential tissue samples from this specific anatomical region, which has been 
reported to be an important site for FMDV replication in both early and persistent stages of 
infection
3,6,21,59,75,80
. Obtained samples were used to investigate the presence of FMDV RNA 
(manuscript 3), as well as the expression of selected inflammatory cytokines (manuscript 2) 
at different stages of infection. The original idea was to harvest biopsy samples, which would 
enable monitoring of the progression of infection within individual animals, with minimal 
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interference to the natural course of infection. The study-design allowed for a comparison of 
possible differences in virus replication and the local tissue response to infection between 
animals that would subsequently develop into FMDV carriers and those that would not. 
Animals were sedated through intravenous injection of xylazine (Rompun vet© 1.5 ml/ 
animal) and positioned in ventral recumbency. A fiberoptic endoscope (Vet-vu 2FSb) was 
introduced through one nostril and positioned to allow clear visualization of the nasopharynx, 
with the entrance of the trachea in central view (Figure 3). Tissue samples were collected 
from the ventral surface (constituting the dorsal soft palate), just to either side of the mid 
plane, rostral to the epiglottis. The site of sampling is believed to house a high density of 
diffuse lymphoid tissue, which has also been corroborated through standard hematoxylin-
eosin (HE) staining of randomly selected biopsy samples (Figure 4). Two pieces of tissue, 
approximately 1x1x1 mm in size, harvested from slightly different locations within the 
sampling area were included in each sample. 
The first biopsy sample from each animal was collected one week prior to inoculation. The 
second biopsy was collected during the acute phase of infection, defined as the first day 
where the animals showed a rectal temperature of above 40
o
C, with a third sample collected 7 
days later. In experiment FMD 3C 2008, a final collection of biopsies was performed at PID 
28. In subsequent experiments, final collection of tissue samples was performed during post-
mortem examinations performed at the termination of the experiments at PID 32-35. 
 
 
 
 
 
 
 
 
 
Figure 3. Endoscopical examination with collection of biopsy samples from sedated calf. 
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a 
     
Figure 4. Hematoxylin-eosin (HE) staining of randomly selected biopsy sample harvested 
form an uninfected calf. The picture shows intact non-cornified stratified squamous epithelia 
(a) with underlying sub-mucosa (b) and lymphoid tissue (c). 
Clinical appearance of infection with FMDV O UKG 34/2001 in cattle 
All animals included in the test groups developed mild to moderate clinical signs of FMD 
(Figures 5-8), with an increase in body temperature and vesicular lesions in the oral cavity 
being the most prominent findings occurring in all individuals. Less than half of the animals 
developed vesicular lesions on the feet and only two individuals (out of 56) developed clearly 
visible lameness (Figure 8). Inoculated animals developed clinical signs of FMD at PID 1-2, 
whilst onset of clinical disease in contact animals was observed from PID 2-5. The animals 
showed no significant loss in appetite and all animals recovered from clinical disease within 
approximately seven days, without further complications, and without the need of supportive 
medical treatment. 
Vesicular lesions within the oral cavity were most commonly found on the dental pad (Figure 
5) and gums in addition to the tongue (Figure 6), which was most affected in animals that 
were infected through direct inoculation. The epithelia overlying the lesions appeared 
thickened and whitish, before being sloughed off within few days. Lesions became covered 
by fibrinous exudate, and healed from below within approximately 5-7 days after initial 
appearance. 
 
b 
c 
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Figure 5. Ruptured vesicles located on the dental pad observed at the first day of appearance 
of clinical symptoms. 
 
Figure 6. Intact vesicle on the tongue of a contact-infected calf during the early phase of 
infection. 
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Figure 7. FMDV-infected calf showing characteristic clinical signs of excessive salivation as 
well as a vesicular lesion on the muzzle during the acute phase of infection. 
 
Figure 8. Acutely infected calf displaying bilateral front limb lameness due to vesicular 
lesions within the hoof-clefts. 
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Figure 9. Vesicular lesions on ruminal septa in a calf which was euthanized during the acute 
phase of infection. This region of the rumen is covered by cornified stratified squamous 
epithelia which makes it susceptible to FMDV replication.  
FMDV O UG 312/2006  
This Ugandan FMDV isolate was derived from a probang sample collected from a cow in 
Mpigi village, Mbarara district, Uganda, in 2006
9
. The sampling and subsequent 
characterization of the virus was performed as a part of the project “Livestock and wildlife 
diseases in East Africa”, funded by the Danish International Developments Agency 
(DANIDA). Sequencing of the structural VP1 region showed that the specific isolate 
belonged to the East Africa -2 (EA2) topotype of FMDV serotype O
9
.  
Virus Inoculum 
The inoculum used for the experiment was prepared through isolation in BTY cell culture, 
within the FMD facilities at Lindholm Island. The infectious titre was determined as 10
6.4
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TCID50/ml, and each inoculated animal received a single dose of 10
6.1
TCID50 through 
subepidermal injection in the tongue. 
Experimental procedure 
The experimental protocol was designed with the aims of reproducing the diverse serological 
profiles which are often found in domestic animals and wildlife in East Africa, with 
combinations of antibodies against several different FMDV serotypes. Within this region, 
domestic animals are generally not subjected to prophylactic FMDV immunizations. 
Vaccination campaigns are, however, often implemented as a measure of combating the 
FMDV outbreaks that occur within specific areas. Domestic livestock are therefore often 
subjected to repeated immunizations with vaccines containing antigens of the FMDV 
serotypes which are currently believed to be in circulation. Serological surveillance is made 
difficult as most animals will have developed antibodies against a mixture of different FMDV 
serotypes, both as a consequence of repeated vaccinations and due to possible exposure to the 
infection.  
By using an immunization protocol with FMDV vaccines produced and commonly used in 
the area, and then subsequently challenging the animals with a locally derived FMDV isolate, 
the purpose of the experiment was to produce sera from animals with a known history of 
FMDV exposure. The sera would subsequently be used for validation and optimization of 
serological assays used for epidemiological surveillance.  
In the experiment (FMD 4C 2009), 12 calves were directly inoculated with the FMDV O 
isolate derived from Uganda. 6 of the animals had been through a six week vaccination 
protocol consisting of three vaccinations, with two different vaccines. Vaccinated animals 
had received one dose of either of two monovalent vaccines with antigen components of 
either serotype SAT-1 or serotype SAT-2, followed by two additional administrations, 
separated by 18 days, of a trivalent vaccine against serotypes O, SAT-1 and SAT-2. 
Challenge with the type O virus was performed 47 days after the animals had received the 
last of the three vaccinations.  
The general design of the experiment, with observations of the clinical progression of the 
infection and collection of routine samples, was similar to what has been described above for 
cattle experiments with FMD O UKG 34/2001. 
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Clinical appearance of infection with FMDV O UG 312/2006 
The vaccination scheme did not protect the animals from developing severe clinical disease 
when subsequently challenged with the Ugandan FMDV O-isolate. The clinical appearance 
of infection resembled that previously described for infection with FMDV O UKG 34/2001, 
although with a significantly increased severity of lesions. Several of the animals received 
supportive treatment with analgesics and anti-inflammatory drugs (Torbugesic 10mg/100kgs 
and Metacam; 0.5 mg/kg) as well as antibiotics (Streptocillin; 5ml/100kgs) in order to 
alleviate the clinical symptoms. The clinical course of infection was, however, quickly 
overcome and all animals recovered fully from the infection within approximately 7 days. 
Results from serological investigations from this experiment have been presented 
elsewhere
70
. 
 
 
Figure 10. Profound sloughing of epithelia in the oral cavity of calf infected with FMDV O 
UG 312/2006. This calf lost all superficial epithelia from the tongue within 1 day after this 
picture was taken. The animal received antibiotic treatment due to a suspected (secondary) 
bacterial infection in the oral cavity. The lesions healed very efficiently, the animal was able 
to eat normally within few days, and there was no chronic damage caused by the infection. 
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Figure 11. Significant sloughing of epithelia from lips, dental pad and gums in calf infected 
with  FMDV O UG 312/2006. This is the same animal as seen in Figure 10. 
 
 
 
 
 
 
 
 
 
 
Figure 12. Severe lesion on the muzzle of a calf during the acute phase of infection with 
FMDV O UG 312/2006. 
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Clinical experiment with FMDV O UKG 34/2001 in sheep 
The experiment FMD 2S 2008 was designed to investigate the clinical appearance of this 
FMDV isolate in sheep. The experiment was designed to include 20, 4-month old, lambs of 
which 12 were directly inoculated through injection in the coronary band of one front limb, 
and remaining animals were infected through continuous contact with the inoculated animals.  
The protocol used for routine sampling was similar to what has been described above for the 
cattle experiments. 
Clinical appearance of infection  
All animals included in the experiment developed mild and transient symptoms of infection. 
19 out of 20 animals developed vesicular lesions in the oral cavity, mainly visible as vesicles 
located at the dental pad and gums which were covered by thickened epithelia that fell of 
within a short period of time. The remaining individual was the only lamb which developed a 
visible foot lesion. This animal, which had not been directly inoculated, developed severe 
lameness on one hind limb and was unwilling to bear weight on this limb due to pain caused 
by clearly visible vesicle in the coronary band. The vesicle ruptured, with complete recovery 
of normal gait within one day of the first appearance of lameness.  
The animals showed a significant increase in body temperature, which lasted only for about 
1-2 days. There was a transient viremia, which was counteracted by the appearance of anti-
FMDV antibodies in the circulation (Figure 16). There was no visible salivation or loss of 
appetite and with the exception of the one individual that showed lameness, the clinical signs 
of infection were only clearly visible through direct examination of the oral cavity.  
An interesting detail of the clinical appearance of infection observed in this experiment is that 
during an experiment performed at the IAH-Pirbright, where sheep were infected with 
FMDV O UKG 34/2001, all animals were reported to have developed lesions in the feet, 
without any observable lesions within the oral cavity (Ryan Waters, personal 
communication).  
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Figure 13. Vesicular lesion on the dental pad of a lamb infected with FMDV O UKG 34/2001  
 
 
Figure 14. Ruptured vesicular lesion on the dental pad of a lamb infected with FMDV O 
UKG 34/2001 
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Figure 15. Vesicular lesion in the coronary band of a lamb infected with FMDV O UKG 
34/2001 
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Results of clinical and serological observations. 
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Figure 16. Results of measurements of temperature, viremia and anti-FMDV O antibodies in 
sera of 20 sheep (12 inoculated and 8 contact infected) infected with FMDV O UKG 34/2001. 
The level of viremia was quantified by qRT-PCR and FMDV O antibodies was measured 
using a solid phase blocking ELISA assay, the methods used are described in detail in 
manuscript number 1. 
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Abstract 
A series of challenge experiments were performed in order to investigate the acute phase 
responses to foot-and-mouth disease virus (FMDV) infection in cattle and possible 
implications for the development of persistently infected “carriers”. The host response to 
infection was investigated through measurements of the concentrations of the acute phase 
proteins (APPs) serum amyloid A (SAA) and haptoglobin (HP), as well as the bioactivity of 
type 1 interferon (IFN) in serum of infected animals.  Results were based on measurements 
from a total of 36 infected animals of which 24 were kept for observational periods exceeding 
28 days in order to determine the carrier-status of individual animals. The systemic host 
response to FMDV in infected animals was evaluated in comparison to similar measurements 
in sera from 6 mock-inoculated control animals.  
There was a significant increase in serum concentrations of both APPs and type 1 IFN in 
infected animals coinciding with the onset of viremia and clinical disease. The measured 
parameters declined to baseline levels within 21 days after inoculation, indicating that there 
was no systemically measurable inflammatory reaction related to the carrier state of FMD. 
There was a statistically significant difference in the HP response between carriers and non-
carriers with a lower response in the animals that subsequently developed into FMDV 
carriers. It was concluded that the induction of SAA, HP and type 1 IFN in serum can be used 
as markers of acute infection by FMDV in cattle. 
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Background 
Foot-and-Mouth-Disease (FMD) is a highly contagious viral disease which affects cloven-
hoofed animals including cattle, sheep and pigs, with substantial financial implications for 
affected countries. Severity of clinical disease varies between common domestic species, 
with pigs developing severe clinical illness, followed by cattle showing obvious but less 
severe clinical signs, whilst the clinical course of the infection in sheep may be very mild
5
. 
Foot-and-mouth disease virus (FMDV) is a positive stranded RNA virus. It is the prototype 
virus of the Aphthovirus genus within the picornavirus family. The viral genome includes a 
single large open reading frame encoding a polyprotein which is cleaved by virus-encoded 
proteases giving rise to structural and non-structural proteins needed for replication and 
assembly of new virus particles
11
.  
The predominant site of initial FMDV replication within infected animals is thought to be 
located within the epithelia of the pharyngeal mucosa
3,17,34,36
, or alternatively within the 
lungs
14,15
. From here the virus spreads via the lymphatics and vascular system to the 
peripheral sites of secondary replication, characterized by the presence of stratified cornified 
squamous epithelia, such as the coronary bands and oral cavity
3
. Infected cattle develop 
transient viremia lasting for 2-3 days, which is effectively counteracted by the development 
of circulating anti-FMDV antibodies. The clinical disease follows a rapid time course and is 
typically manifested by a sudden rise in body temperature and development of vesicular 
lesions at peripheral areas of viral replication. Affected animals may display varying degrees 
of salivation, inappetence and lameness corresponding to the severity of lesions. The clinical 
course of the infection usually subsides within 7-14 days but the potential development of 
persistently infected carrier-animals creates further complications for disease control. FMDV 
carriers are defined as animals with asymptomatic, intermittent, presence of infectious virus 
in oropharyngeal fluid more than 28 days post infection (dpi)
38
. 
It is believed that in these animals (approximately 50% of infected cattle), FMDV is capable 
of persisting, at a low level, within pharyngeal epithelial cells
16,52
, or as intact, but largely 
quiescent, viral particles within germinal centers in pharyngeal tissues
31
. Since carrier 
animals are a potential source of infectious virus, their presence is unacceptable in areas free 
of FMD. 
Development of the carrier state is unaffected by the presence of neutralizing antibodies in 
the circulation. Thus, both animals that are immunologically naïve at the time of exposure to 
FMDV, as well as those with circulating antibodies due to vaccination or previous exposure 
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to the virus can become FMDV-carriers, regardless of pre-occurring clinical disease
16,22,38
.  It 
is known that FMDV carriers do exhibit a measurable adaptive immune-response comparable 
to that of animals that clear the infection
4
 but there is still a significant lack of knowledge 
regarding the innate immune-response to FMD in cattle. The duration of the carrier state 
varies between species, with the longest duration recorded in African buffaloes (5 years), 
followed by cattle (2 years) and sheep (9 months)
19,33,35,43
.  Pigs do not become carriers
4
 
The innate immune response induced by a viral infection in the upper respiratory tract is 
characterized by initial activation of peripheral primary effector cells which function to 
initiate a local inflammatory response, priming and recruiting activators of the cellular 
immune response. Macrophages present in the respiratory tract produce pro-inflammatory 
cytokines such as tumor necrosis factor-α, interleukin-1 and interferon (IFN) upon 
stimulation of pattern recognizing surface receptors, causing alterations in local vascular 
walls, and providing recruitment and activating stimuli to antigen presenting cells and 
phagocytes
10,47
. 
Type 1 IFNs are also known as viral IFNs and include interferon-α and -β. These IFNs are 
secreted by virus infected cells with the function of blocking spread of virus to uninfected 
cells by inducing alterations in gene transcription and protein synthesis following their 
interaction with common cell-surface interferon receptors
29,39,47
. It has been proposed that 
type 1 IFNs may have an important role in the host response to FMDV
4,18,44
 and that the 
ability of the virus to induce an IFN response may be related to the pathogenicity of different 
isolates of FMDV
13,20
. 
Locally produced pro-inflammatory mediators also cause alterations in hepatic metabolism, 
inducing the production of various acute phase proteins (APPs) in the circulation
10
. APPs 
have been defined as proteins for which serum concentrations are significantly altered in 
acutely infected animals, compared to that of animals which are clinically healthy
24
. The 
proteomic pattern of the acute phase response varies between animal species and also 
depends upon the pathogen responsible for inducing the response
25,37
.  
Previous studies have shown a correlation between increased serum levels of bovine 
haptoglobin (HP) and the onset of clinical disease in bovine respiratory disease
24
, as well as 
in infections with bovine respiratory syncytial virus
27
. Increased serum concentrations of HP 
in cattle acutely infected with FMDV through aerosol exposure, have also been 
demonstrated
28
. 
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The production of HP and serum amyloid A (SAA) are considered reliable indicators of acute 
inflammation caused by various infectious agents in cattle
30
. 
The aim of this study was to investigate the innate immune response to infection with FMDV 
in cattle by measuring systemic levels of acute phase proteins SAA and HP as well as the 
biological activity of type 1 IFN in serum. Results from these measurements were evaluated 
in relation to the timing of the appearance of clinical signs of disease as well as the detection 
of viremia and circulating antibodies. Measured parameters were further analyzed statistically 
in order to evaluate whether there was any detectable difference in host response between the 
animals that developed into persistently infected carrier animals and those that were efficient 
in clearing the infection completely. 
Materials and Methods 
 Animal experiments and samples 
Animal experiments were performed in high containment research facilities at DTU-Vet, 
Lindholm Island, Denmark, in accordance with the requirements of the Danish Animal 
Experiments Inspectorate (License 2003/561-742; 2008/561-1541). 
Three independent experiments were included in this study. The animals used were 4-5 
month old steers of mixed-Holstein breed. The first experiment (FMD 2008) was performed 
with 12 animals (six inoculated and six in direct contact). In each of the two subsequent 
experiments (FMD 2010 a + b), three un-infected control animals, kept in a separate isolation 
unit, were used in addition to the twelve test animals. Results from this study are thus based 
on measurements in 36 FMDV infected animals and 6 un-infected controls. Apart from 
observations of clinical signs of disease and measurements of standard para-clinical 
parameters such as virus excretion and development of circulating antibodies (see description 
of protocol below), all three experiments included assays for the serum concentrations of the 
APPs (SAA and HP) as well as for the bioactivity of type 1 IFN in serum. In the first 
experiment (FMD 2008) animals were kept under observation for a total of 100 days post 
infection, whilst the experimental periods for the two subsequent experiments (FMD 2010 
a+b) were 35 and 14 days post infection respectively. The following protocol was used in all 
three experiments. 
All animals were pre-treated using a broad spectrum antibiotic (enrofloxacin; “Baytril©”; 2.5 
mg/kg) for four days upon arrival in order to reduce the level of any existing bacterial 
     
 
51 
 
infection. Animals were subsequently allowed a period of acclimatization of a minimum of 
10 days, and were further treated with β-lactam penicillin (”streptocillin©”; 5ml/100kg) for 
four days around inoculation to avoid interference caused by any bacterial infections. 
Six animals were inoculated with FMDV O UKG 34/2001 (original inoculum obtained from 
the Institute for Animal Health (IAH)-Pirbright, and then passaged once in cattle) using 
subepidermo-lingual injection, each animal receiving approximately 10
6.9
 TCID50 in a volume 
of 0.5 ml administered at 6 to 8 injection sites at the base of the tongue. A standard protocol 
for sedation consisting of intravenous injection of Xylazinhydrochloride (Rompun© 2%; 1,5 
ml/ animal) was used for inoculation and the sedation was reversed through intravenous 
administration of Antipamezol (Antisedan©; 0,5 ml/ animal). Six other animals were kept in 
continuous direct contact with the inoculated animals, with two inoculated plus two contact 
animals in each pen and with the stable facilities allowing direct contact between animals in 
separate pens. 
All animals were monitored daily, with measurements of rectal temperature and observation 
of clinical signs. Serum samples were collected daily from 3 days prior to inoculation and 
throughout the first two weeks of the experiments and thereafter on a weekly basis 
throughout the remaining part of the experiment.  Blood samples were stored at 4
o
C 
overnight, before centrifugation and the sera were subsequently stored at -70
o
C.  
Samples of oropharyngeal fluid (probang samples)
45
 for quantification of virus excretion, in 
order to define the carrier status of individual animals
50
, were collected prior to inoculation, 
once daily during the first week after inoculation, then every other day throughout the second 
week and on a weekly basis subsequently. Probang samples were collected at closer intervals 
from post infection day (PID) 28 until termination of the experiment so that the carrier status 
of individual animals was based on the analysis of a minimum of four samples. Control 
animals were handled and sampled following a protocol similar to that used for infected 
animals. The animals were sedated and “mock-inoculated” using phosphate buffer, in order to 
mimic the procedure used for inoculation and sample collection in the test groups. 
 Quantification of Acute Phase Proteins in serum 
 Serum Amyloid A  
Serum concentrations of SAA were determined using a sandwich-ELISA kit (Tridelta 
Developments Ltd. Maynooth, County Kildare, Ireland). Samples were analyzed at a dilution 
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of 1:500, according to the manufacturer’s instructions. A standard dilution of the SAA 
calibrator included in the kit was added in duplicate to each of the ELISA plates and SAA 
concentrations in the sera were determined from the standard curves. 
Haptoglobin 
Serum concentrations of HP were determined using a sandwich-ELISA, following a protocol 
described in detail previously
27
 using monoclonal anti-bovine haptoglobin antibodies kindly 
provided by Dr. Philip Griebel, University of Saskatchewan, Canada. 
Briefly, microtitre plates were coated with anti-bovine haptoglobin ascites fluid in carbonate 
buffer. Serum samples were tested at three dilutions (1:100; 1:300; 1:900), together with a 
calibration standard of acute phase serum with known concentrations of HP. Bound antigen 
was detected using biotinylated anti-bovine haptoglobin Mabs, by staining with TMB reagent 
in citrate buffer. The colour development was terminated by addition of sulfuric acid, and 
OD-values were read using a standard ELISA reader at wavelengths of 450/650nm. 
Quantification of the bioactivity of Type 1 IFN in serum  
Biological activity of type 1 IFN was quantified with an Mx/CAT reporter gene assay
23
, 
using the transfected MDBK-t2 cell line kindly provided by Dr. Bryan Charleston (IAH-
Compton, UK). Briefly, the cells were seeded in 24-well plates and cultured in 1500µl of 
medium (EMEM with blasticidin (10µg /ml), penicillin (100 IU /ml), streptomycin (100µg 
/ml) and 10% FCS). 
Serum samples, diluted 1:5 in cell culture medium containing 2% FCS, were added to the 
cells and incubated overnight at 37
o
C. All samples were tested in duplicate, in parallel with 
standard concentrations (0.125 to 90 IU/ml) of recombinant human IFN-α (Invitrogen). Cells 
were harvested and CAT-expression was quantified using a commercial CAT-ELISA kit 
(Roche Applied Science) following the manufacturer’s instructions. 
Quantification of anti-FMDV antibodies using a solid phase blocking ELISA 
Serum concentrations of FMD specific antibodies were measured using a serotype-specific 
solid phase blocking ELISA
9
. In brief, microtitre plates were coated with guinea-pig immune 
sera raised against FMDV O Manissa before addition of inactivated FMDV antigen. Samples 
of the bovine sera were then added, incubated overnight and then rabbit anti-FMDV serotype 
O serum was added  and the bound antibodies were detected using horseradish-peroxidase 
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conjugated porcine anti-rabbit IgG.  All serum samples were initially screened at a dilution of 
1:5 and positive samples (blocking percentage >50%) were analyzed in a two-fold titration 
starting at a dilution of 1:10 to allow determination of antibody titers. 
Quantification of viremia and excretion of FMDV RNA in probang samples 
Quantification of FMDV RNA in serum and probang samples was performed using 
quantitative RT-PCR
50
. Total RNA was extracted using a MagNa Pure LC Total Nucleic 
Acid Isolation Kit (Roche) with an automated robotic workstation (Roche) from 200µl of 
sample, according to the manufacturer’s instructions. Each RNA sample was eluted in a 
volume of 50µl and stored at -70
o
C until further processing. Reverse transcription of FMDV 
RNA was carried out using 6µl of extracted RNA in a total volume of 15µl, using a TaqMan 
RT kit with random hexamer primers (Applied Biosystems) at 48
o
 C for 45 minutes and 95
o 
C
 
for 5 minutes. Then 7µl of each cDNA was mixed with 18µl of 2x TaqMan universal PCR 
mastermix (Applied Biosystems) containing 22.5 pmol of each primer and 5 pmol of 
fluorescently labeled probe. PCR amplification was carried out for 50 cycles, in an Applied 
Biosystems Model Mx 3005P Thermal cycler and analysed using MxPro qPCR software. 
Statistics 
APP responses were log-transformed and a response measure representing the area under the 
curve was constructed, where linear interpolation between points of observations was used, 
and a slight extension at end points to put equal weight on observations evenly spaced in 
time. APP responses were analyzed with a standard random effects model 
8
, where the 
identification of the three sequentially performed experiments (“survey”) was entered as a 
random effect.  Fixed effects were Carrier status (“Carrier”), route of infection (“status”: 
inoculated, contact or control), level of viremia and maximum anti-FMDV antibody titre. The 
effect of the carrier-status of individual animals was modeled as a covariate with the values 
1/0 representing carrier/ non-carrier. Tests were performed as likelihood ratio tests, according 
to the following model, 
log(AUCij) = βAlog(Antibodies)ij + βVViremiaij + βCCarrierij + βStatus.ij + ηYSurvey.i + εij, 
i=1:3,j=1:ni, 
where β represents coefficients of effect and η represents the standard deviation between 
experiments (i). 
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Model control was performed with standard techniques. For the APP SAA, the model control 
revealed that criteria were not met for the response measure, and the tests were subsequently 
performed as z-tests (continuous fixed effects). All analyses were performed with Splus
©
 
software version 6.1 (Insightful Corp. 2002). 
Results 
Clinical symptoms 
All animals included in the test groups developed mild to moderate clinical signs of FMD, 
with an increase in body temperature (Figure 1a) and vesicular lesions in the oral cavity being 
the most prominent findings occurring in all individuals. Less than half of the animals 
developed vesicular lesions on the feet and only one individual (out of 36) developed clearly 
visible lameness. Inoculated animals developed clinical signs of FMD at PID 1-2, whilst 
onset of clinical disease in contact animals was observed from PID 2-5. The animals showed 
no loss in appetite and all animals recovered from clinical disease within approximately 
seven days, without further complications, and without the need of supportive medical 
treatment. 
Viremia and development of circulating antibodies 
FMDV RNA was detectable in serum from all infected animals for a period of four to seven 
days (Figure 1b). Inoculated animals showed significant viremia at PID 1, reflecting the very 
rapid replication and systemic spread of FMDV. Anti-FMDV serotype O antibodies in serum 
reached the diagnostic cut-off level, defined as a blocking percentage of 50%, at around PID 
4 to 5 in inoculated animals and at PID 7 to 9 in the contact group (Figure 1c). Appearance of 
circulating antibodies was accompanied by a rapid reduction in viremia. There were no 
detectable differences in the level of viremia (presented as the number of copies of FMDV 
genome per µl of serum) or the anti-FMDV O antibody titres (data not shown) between 
directly inoculated and contact infected animals, or between carriers and non-carriers. 
Prevalence of Carriers 
Carrier status was determined on the basis of detection of FMDV RNA, using qRT-PCR, in 
probang samples beyond 28 days post infection
50
. An animal was regarded as being a carrier 
following detection of at least two positive probang samples (Ct value < 40) out of a 
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minimum of four samples collected beyond PID 28. Detailed information on the extent of 
virus excretion in probang samples in carriers and non-carriers has been included in a 
separate report
41
. In summary, animals identified as FMDV carriers had detectable levels of 
FMDV RNA (Ct<40) in probang samples harvested throughout the entire length of the 
experimental period whereas FMDV RNA became undetectable in probang samples from the 
non-carriers by approximately 14 days post infection. One of the experiments (FMD 2010b) 
was terminated at 14 days post infection, for technical reasons, and so it was therefore not 
possible to determine carrier-status in this experiment. In the remaining two experiments 
(FMD 2008 and FMD 2010a) the prevalence of carriers was 6/12 (50%) and 3/12 (25%) 
respectively (see Table 1), consistent with what has been found previously in experimental 
infections with FMDV 
2,5,35
 
Acute phase proteins 
 The serum levels of APPs showed a consistently occurring peak, coinciding with the onset of 
clinical symptoms (Figure 1e-f). Directly inoculated and contact animals showed similar 
responses when the areas under the curve (AUC) were compared for the serum 
concentrations of SAA during the observation period of 14 days after infection. For the HP-
response, there was however, a small but statistically significant difference (p=0.04) between 
inoculated and contact animals, with a larger response in the directly inoculated animals. 
There was a very marked and statistically significant (p<0.0001) difference in the AUC 
values for both SAA and HP when comparing test-groups (FMDV inoculated and contacts) to 
the uninfected control animals. 
It is interesting to note that, there was also a statistically significant difference (P=0.015) in 
the AUC values for the serum concentration of HP between the animals that became carriers 
and the non-carriers, with lower values in the carrier animals (Figure 2f; table 2 and 3). The 
difference in the HP-response between carriers and non-carriers was unrelated to, and could 
therefore not be explained by, the observed difference between inoculated and contact-
infected animals for this parameter. There was no difference in the AUC values for serum 
concentration of SAA between carriers and non-carriers (Table 2). 
Type 1 IFN 
Type 1 IFN bioactivity, as measured by the activation of the Mx promoter in the MDBK-t2 
cells, showed a reaction pattern similar to the APPs, with a marked peak at the onset of 
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clinical symptoms and thus significant differences in response between the infected test-
groups and uninfected control animals. Contact animals seemed to show slightly lower peaks 
in IFN response than directly inoculated animals (Figure 1d), although this difference was not 
statistically significant (Table 2). There was no difference in the AUC values for the type 1 
IFN bioactivity between carriers and non-carriers (Table 2). 
Discussion 
The observed progression of the clinical infection, including the level of viremia  and titres of 
circulating antibodies, was similar to what has been described previously for infection with 
FMDV O UKG/34 2001 in cattle
1,49
. 
Measurements of serum concentrations of the APPs, SAA and HP, indicated a rapid acute 
phase response which coincided with the appearance of clinical signs of disease. It has 
previously been proposed that the sensitivity of SAA as a marker of infection could be higher 
than that of HP
30
. In our studies we observed a relatively high basal level and measurable 
changes in the level of SAA in some of the mock-inoculated control animals, although by no 
means approaching the significantly up-regulated concentrations observed in animals infected 
with FMDV. In contrast to this, we recorded very low basal levels in the HP measurements 
within uninfected animals, whilst both APP markers showed a clear response with 
significantly increased concentrations within the sera from infected animals.  It has been 
shown that changes in SAA levels are more easily induced by physical stress than for HP
7
.  It 
may be that the procedures used for handling of animals for sampling, including the protocol 
for sedation used for inoculation, could be responsible for inducing a significant stress 
response in the animals, which might be the cause of the observed SAA response in some of 
the mock-inoculated control animals.  
The acute phase response to FMD in cattle has previously been investigated by Hofner et al.
28
 
using measurements of HP in sera from cattle that were infected with FMDV O BFS 1860 
following aerosol exposure. It was reported that an increase in serum concentrations of HP 
occurred 8-9 days after virus exposure and 1-3 days after the onset of viremia and appearance 
of clinical signs. It was concluded that there was no measurable rise in HP during the “pre-
viremic” phase of FMD infection. Furthermore, it was proposed that this finding was 
indicative of little or no tissue damage during initial replication of FMDV in the pharyngeal 
epithelia. 
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The clinical course of FMD in our experiments differed slightly from what was described by 
Hofner et al.
28
. We observed a more rapid course of infection, with simultaneous appearance 
of viremia and clinical signs of disease, including an increase in body temperature, in both 
directly inoculated and in contact animals. We also detected an increase in serum 
concentrations of HP as well as SAA, which for the majority of the animals began at the same 
time as the observed onset of clinical disease and appearance of viremia. Thus, there was no 
apparent lag phase between the rise in body temperature and the measurable acute phase 
response in serum.  
The differences in clinical observations may partly be a result of the different means of 
inoculation used in the two studies; direct inoculation in our studies versus aerosol exposure 
in the study performed by Hofner et al.
28
. However, in our studies, we also saw similar timing 
of reactions in animals infected by contact exposure as in those that had been directly 
inoculated with simultaneous detection of viremia and clinical parameters. Thus, the 
observed variations in results are more likely to be derived from differences in sensitivity of 
the different assays used for quantification of HP and detection of viremia in the two studies. 
In the earlier study, the HP concentration was quantified through an assay measuring 
hemoglobin binding capacity while viremia was detected by inoculation of primary cell 
cultures, whereas we measured HP with a specific and sensitive ELISA assay and viremia 
with a quantitative RT-PCR.  
The measured changes in the bioactivity of type 1 IFN in serum followed a similar pattern to 
what was recorded for the APPs, with measurable peaks in activity of IFN in the sera at the 
onset of clinical disease. There seemed to be a slight, although not statistically significant, 
difference in maximum peak levels of IFN bioactivity in inoculated versus contact animals. 
Animals in the contact groups acquired the infection through continuous exposure to virus 
excreted by infected animals, whereas the inoculated animals received a single high level 
dose of virus in the tongue. The different level and route of virus access to the primary site of 
replication is likely to cause a variation in the timing and synchronization of the initial 
cellular immune response responsible for the measured cytokine response. 
It is believed that the acute phase response of the liver is induced in response to the presence 
of inflammatory cytokines in the circulation
10
. Our results indicate near simultaneous timing 
for the onset of induction of APPs and type 1 IFN in both inoculated and contact-infected 
animals, with the rate of the initial response in SAA slightly exceeding that of HP. It is 
possible that the very rapid onset of viremia, with high levels of virus in the blood seen as 
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early as PID 1 in the inoculated animals, could in some way influence the hepatic APP 
response in a more direct manner. 
Type 1 IFN is produced by virus-infected cells, as well as by inflammatory cells 
(macrophages and cells of the dendritic cell lineage) present within the circulation and 
peripheral tissues
21,48
. Previous studies have shown an up-regulation of IFN-α and-β mRNAs 
within epithelial cells harvested from FMDV lesions of the oral cavity
48
. We have attempted 
to quantify IFN bioactivity in samples of oropharyngeal scrapings (probang samples) without 
any success (data not shown), possibly indicating that the activity of IFN is somehow 
inhibited in this type of sample.  
Recent studies in cell culture have demonstrated that the leader protease (Lpro) of FMDV is 
capable of down-regulation of transcription of IFN-β through interaction with NFκB20,46. The 
Lpro also inhibits host cell protein synthesis
12,32
, thus within FMDV-infected cells the 
expression of IFN mRNA and its translation should be blocked. This may suggest that the 
IFN present in serum is not produced by cells that are actually infected with FMDV but by 
populations of immune cells that react upon the presence of virus through activation of 
pattern recognizing receptors. Plasmacytoid dendritic cells, also referred to as natural 
interferon producing cells (NIPC), are known to produce high levels of type I IFN in response 
to virus infection
40
. It is, however, also suggested that it is necessary for non-enveloped 
viruses such as FMDV to be complexed by bound antibody in order to induce IFN production 
by cells of this lineage
26
. This putative relationship does not match the timing of events 
observed in our study as the increase in  type 1 IFN activity in serum was detected very early 
(PID 1-2) which significantly precedes the rise in circulating anti FMDV-antibody. 
Investigations of the cellular source of the systemically measurable rise in IFN activity might 
help to further elucidate the interactions between the virus and the immune response of the 
host. Previous studies have reported an increase in IFN-α mRNA levels in nasal associated 
lymphoid tissue harvested from the pharyngeal region of calves acutely infected with FMDV 
serotype O 
51
. The same study also reported a difference in the expression of tumor necrosis 
factor-α (TNF-α) between carriers and non-carriers in similar samples collected from a total 
of 6 animals at 62 days post infection. We have been unable to find evidence of an up-
regulation in IFN mRNA levels in samples of pharyngeal mucosa collected at sequential time 
points during infection. However, we did corroborate the previous report of a difference in 
TNF-α mRNA expression in the pharyngeal epithelium of FMDV-carriers and non-carriers 
during the late phase of infection (>PID 28)
42
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Alsemgeest et al.
6
 compared serum concentrations of SAA and HP in acute and chronic 
inflammation in cattle. It was found that the HP/SAA ratio differed during different stages of 
infection, with the serum concentration of SAA exceeding that of HP in acute inflammation 
and the opposite occurring during chronic inflammation. In our studies, we saw that 
concentrations of both SAA and HP declined to baseline-levels by PID 14-21, regardless of 
whether the animal was persistently infected with FMDV or not. These findings indicate that 
the carrier status in FMDV infection in cattle is not accompanied by a state of systemically 
measurable chronic inflammation. 
There was no measurable difference in the serum reactions of SAA and type 1 IFN between 
infected animals which became carriers or non-carriers. For HP, however, there was a 
statistical difference in the AUC values between animals which were identified subsequently 
as carriers and non-carriers with a lower HP level in carriers. The observed difference in the 
HP response is most clearly visible at the latter part of the timescale when viewing the log-
transformed data (figure 2f). This data may be an indication of slightly prolonged reaction in 
HP in the sera of the animals that were successful in clearing the infection completely. When 
extending the observational period to include analysis of sera collected at PID 21 it was, 
however, clear that the serum concentration of HP did decline to baseline levels (undetectable 
serum concentrations) in all animals regardless of carrier-status.  
The observed difference in HP-response between directly inoculated and contact infected 
animals, which only just reached statistical significance (p=0.04), could possibly (as 
previously discussed for the IFN-response), be explained by the differences in the routes and 
timing of virus exposure.   
The relationship between the HP response and the development of FMDV carrier animals 
should be further investigated in future experiments to elucidate the nature of the apparent 
difference in the acute host response to FMDV between carriers and non-carriers. 
There might also seem to be a slight difference in the time course of SAA and HP responses 
between animals which became carriers and non-carriers, with a more rapid pattern of 
reactions in the carrier-group. This apparent difference is, however, most likely caused by a 
variation in the timing of the reactions between inoculated and contact animals, with a 
relatively larger number of inoculated animals, compared to contact-infected animals within 
the group of carriers. However, the route of infection (directly inoculated versus contact-
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infected) did not have any effect on whether the animal developed into a persistently infected 
carrier or not (Table 1). 
Observations from our experiments indicate that combined measurements of serum 
concentrations of SAA and HP can be used as markers of an acute systemic response to 
FMDV infection in cattle. This could, for example, be of value during vaccine studies or 
transmission experiments with FMDV isolates of low virulence, where it would be of interest 
to detect any systemic immune response in animals exposed to the virus. Studies comparing 
the patterns of the systemic acute phase response in experiments with FMDV isolates of 
varying virulence have been initiated. Preliminary results indicate a close relationship 
between the timing and magnitude of the serum APP response with the severity of clinical 
disease, providing an objective tool for validation of severity of infection. 
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Table 1 
Distribution of FMDV carriers within the directly inoculated and contact infected animals. 
 
 
 
 
 
 
Table 2 
Summary of P-values for comparisons of the AUC values of serum concentrations of APPs 
and IFN during a test period of 14 days after inoculation. 
Levels of significance: ***= p<0.0001; **= p<0.001 *=p<0.05 
 
  Inoculated and 
Contacts vs 
Controls  
Inoculated vs 
 Contacts 
Carriers vs.  
Non-Carriers 
   
SAA   <0.0001*** 0.61  0.49 
 
0.27 
 
IFN 
  
<0.0001*** 
 
0.43 
 
                         
     
Haptoglobin   <0.0001*** 0.04*  0.015* 
     
 
 
 
 
 
 
 
Experiment 
ID 
Number of animals 
(Inoculated: 
Contact) 
Carriers  
(Inoculated: 
Contact) 
Non-Carriers 
(Inoculated: 
Contact) 
FMD 2008 12 (6:6) 6 (4:2) 6 (2:4) 
FMD 2010 a 12 (6:6) 3 (1:2) 9 (5:4) 
     
 
67 
 
Table 3 
Coefficients of effect (β) for contribution to AUC values of serum HP of individual animals 
for statistically significant effects: carrier-status (“Carrier”: carrier (1)/ non-carrier (0)), route 
of infection (“Status”: inoculated/ contact-infected (uninfected controls are not included in 
this analysis as these do not become carriers)).  η represents standard deviation between 
experiments (i) 
 
Final model log(Hpij) = βCCarrierij +   βStatusij +ηYSurveyi + εij, i=1:3,j=1:ni, 
 
  βC 95% confidence interval 
Carrier 
Status 
Carrier 
 
-1.14   -1.98<<-0.3 
 Non-carrier 0  (NA) 
  βStatus  95% confidence interval 
Route of 
infection 
Inoculated 4.52 3.19<<5.85 
 Contact 3.65 2.34<<4.96 
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Figure 1 
 
 
 
Temperature
0 5 10 15
36
38
40
42
Inoculated
Contacts
Controls
Lesions Inoculated
Lesions Contacts
PID
te
m
p
. 
o
 C
Viremia
5 10 15
10 - 1
100
101
102
103
104
105
106
107
Inoculated
Contacts
Controls
PID
c
o
p
ie
s
/ 
l
FMDV O Antibody
0 5 10 15
0
20
40
60
80
100
Inoculated
Contacts
Controls
Diagnostic cut-off
PID
B
lo
c
k
in
g
 %
Type I IFN
0 5 10 15
0
10
20
30
Inoculated
Contacts
Controls
PID
IF
N
 i
u
/m
l
SAA
0 5 10 15
0
50
100
150
Inoculated
Contacts
Controls
PID
S
A
A

g
/m
l
1a
1b
1c
1d
1e
1f
 Haptoglobin
0 5 10 15
0
1000
2000
3000
4000
Inoculated
Contacts
Controls
PID
H
a
p
to
g
lo
b
in

g
/m
l
 
Characterization of clinical signs and acute phase responses in FMDV-infected cattle. 
The results shown are the mean values (+/- S.E.M) for the indicated parameters from three 
separate experiments each including 12 or 15 cattle (6 inoculated with FMDV, 6 in-contact 
and 3 uninfected controls in 2 of the experiments). a) Temperature and timing of occurrence 
of characteristic vesicular lesions within the oral cavity. b) Viremia measured by qRT-PCR 
expressed as copies of FMDV genome/ µl of serum c) anti-FMDV (type O) antibodies in 
serum expressed as blocking percentage derived from a solid phase blocking ELISA d) 
Bioactivity of type 1 IFN in serum (iu/ml) E) Haptoglobin in serum (µg/ml) f) Serum 
Amyloid A in serum (µg/ml). 
 
     
 
69 
 
Figure 2 
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Comparison of acute phase protein and IFN measurements in carrier and non-carrier 
cattle on linear (a-c) and logarithmic scale (d-f). a+d) Bioactivity of type 1 IFN in serum 
(iu/ml) b+e) Serum amyloid A in serum (µg/ml) c+f) Haptoglobin in serum (µg/ml) 
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Abstract 
A novel technique of endoscopical collection of small tissue samples from the pharyngeal 
mucosa of live cattle has been developed. This methodology was used to obtain sequential 
tissue samples from the dorsal soft palate (DSP) of individual cattle infected with foot-and-
mouth disease virus (FMDV) at different phases of the infection. Levels of mRNAs  
encoding interferon (IFN)-α and-β as well as tumor necrosis factor-α (TNF-α) were measured 
in these samples using quantitative RT-PCR assays. Expression levels of IFN-β mRNA were 
significantly down-regulated in the biopsy samples harvested during the acute phase of 
infection, whereas there was no statistically significant effect on the expression of the IFN-α 
mRNA compared to baseline levels. In contrast, the TNF-α mRNA was significantly up-
regulated in samples collected during both acute and late (>28 dpi) phases of infection. There 
were also significantly higher levels of TNF-α mRNA expressed in samples derived from 
animals that were identified subsequently as persistently infected FMDV-carriers. It was 
concluded that there was a significant difference in the host response in the DSP of calves 
that were detected as persistently infected, subclinical carriers of FMDV.  
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Introduction 
Foot-and-mouth disease (FMD) is a highly contagious viral infection of huge financial 
importance for countries with substantial exports of agricultural products. The disease affects 
cloven hoofed animal species such as pigs, cattle and sheep with rapid spread amongst 
susceptible animals. The infection is typically manifested through an increase in body 
temperature and the development of characteristic vesicular lesions in areas covered by 
cornified epithelia such as the oral cavity and coronary bands (reviewed by Alexandersen et 
al.
5
). Mortality rates are low amongst adult animals but the occurrence of persistently 
infected subclinical “carriers” of FMD-virus (FMDV) in ruminant species causes further 
complications for disease control. FMDV carriers are defined as animals with an intermittent 
presence of infectious FMDV in oropharyngeal excretions more than 28 days after initial 
infection
23
.  
FMDV carriers generally mount an adaptive immune response comparable to that seen in 
animals which are effective in clearing the infection, with rapid development of high titres of 
anti-FMDV antibodies in the circulation
4
. A possible difference in the characteristics of early 
FMDV infection in carriers versus non-carriers, with indications of a difference in the rate of 
decline in virus excretion in oropharyngeal fluid following the acute clinical infection has 
been reported
35
. There has also been a report of higher levels of FMDV-specific IgA 
detectable in the oropharyngeal fluid of cattle that were identified as FMDV-carriers 
following vaccination and subsequent virus challenge
21
. There is, however, a lack of specific 
knowledge regarding the innate immune response to FMDV in cattle and its possible role in 
the development of persistently infected carriers. 
FMDV is a positive stranded RNA virus belonging to the Aphthovirus genus within the 
picornavirus family.  The viral genome consists of a single copy of RNA encoding a 
polyprotein from a single large open reading frame. Individual virus proteins are produced by 
the action of the virus encoded leader- (Lpro) and 3C- proteases giving rise to the structural 
and non-structural proteins needed for viral RNA replication and assembly of new virus 
particles
7
. The Lpro of FMDV is also responsible for inhibition of host cell protein synthesis 
through cleavage of cellular translation initiation factors essential for cap-dependent 
translation of host cell mRNAs
7,17
. 
Virus infections of the upper respiratory tract are usually sensed by effector cells of the innate 
immune system, such as macrophages and other cells of the monocyte-lineage, which are 
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present in the respiratory mucosa. Activation of pattern recognizing cellular receptors leads to 
production of an array of pro-inflammatory cytokines, including tumor necrosis factor –α 
(TNF-α) and the type 1 interferons (IFNs). TNF-α is a “common” pro-inflammatory cytokine 
with the function of inducing a local inflammatory reaction. The type 1 IFNs, including IFN-
α and –β, function by interacting with common cell-surface interferon receptors leading to 
downstream induction of transcription of a number of genes involved in preventing spread of 
virus to uninfected cells
24,30
. Induction of type I IFNs has been reported to occur through 
signaling pathways involving NF-кB as well as interferon regulatory factors 3/714 by 
activation of either one of two complementary receptor systems
27
. The first pathway of 
activation is through a class of ubiquitously expressed cytosolic receptors which function to 
detect viral nucleic acids in infected cells and can be found in almost all types of nucleated 
cells
27
. The second class of receptors comprises the Toll-like receptors (TLRs) which belong 
to a family of pattern recognizing receptors (PRRs) that detect molecular features shared by 
entire classes of pathogens
11
. The TLRs involved in the host response to virus infections are 
mainly located in the membranes within intracellular compartments of phagocytic cells
11
, as a 
result of this, the TLR induced pathway of IFN activation does not require that the cell itself 
is actively infected by the virus
27
. 
It has been demonstrated that it is necessary for FMDV to be complexed with 
immunoglobulins in order to induce transcription of IFN by porcine plasmacytoid dendritic 
cells in culture
13
. We have previously reported a consistent and clearly detectable systemic 
acute phase response in cattle experimentally infected with FMDV serotype O that is 
characterized by an increase in the bioactivity of Type 1 IFN in serum and by up-regulated 
concentrations of the acute phase proteins (APPs) serum amyloid A and haptoglobin
26
. The 
increase in APPs and type 1 IFN within serum was coincident with the onset of clinical signs 
of infection. The rise in IFN occurred at a much earlier time point than the detection of anti-
FMDV antibodies in the circulation and has therefore indicated the need for further 
investigations of the cellular source of the IFN response. 
Clinical studies investigating the pathogenesis of FMD in cattle have detected the persistence 
of FMDV in epithelial cells
36
 and germinal centers
15
 of the pharynx.  The pharyngeal 
epithelium has also been reported to be involved in FMDV replication during the early phases 
of infection
3,8,18,20
 and this specific anatomical site is therefore of significant interest when 
investigating  FMDV pathogenesis.   
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The aim of this study has been to investigate the local tissue response, through quantification 
of mRNA levels encoding IFN-α and -β, as well as TNF-α in tissue samples collected from 
the pharyngeal mucosa of FMDV infected cattle. The cytokine mRNA expression profiles 
were analyzed in order to detect potential differences in the local tissue response of the 
pharyngeal epithelia, during both acute and chronic phases of the infection, between animals 
that developed into FMDV carriers and those that did not. 
 
Materials and Methods 
Animal experiments and samples 
Animal experiments were performed in biosecure research facilities at DTU-Vet, Lindholm 
Island, Denmark, in accordance with the requirements of the Danish Animal Experiments 
Inspectorate (License 2003/561-742; 2008/561-1541). Three independently performed 
experiments, using a similar experimental set up, were included in this study (see Table 1).  
Each of the experiments included 12 steers (4-5 months old) of mixed-holstein breed. The 
general experimental protocols have been described in detail elsewhere
26
. In brief, six 
animals in each experiment were inoculated with FMDV O UKG 34/2001 (original inoculum 
obtained from IAH-Pirbright, UK, and then passaged once in cattle) using subepidermo-
lingual injection, each animal receiving approximately 10
6.9
 TCID50 in a volume of 0.5 ml.  
Six other animals were kept in continuous direct contact with the inoculated animals, with 
two inoculated plus two contact animals in each pen and with the stable facilities also 
allowing direct contact between animals in separate pens. 
All animals were monitored daily, with measurements of rectal temperature and observation 
of clinical signs. Serum samples were collected daily from 3 days prior to inoculation and 
throughout the first two weeks of the experiments but then on a weekly basis throughout the 
remainder of the experiment.   
Samples of oropharyngeal fluid (probang samples) were collected, for the quantification of 
virus shedding, as well as for determining the carrier status of individual animals. Samples 
were obtained prior to inoculation, once daily during the first week after inoculation, then 
every other day throughout the second week and on a weekly basis subsequently. Additional 
samples were collected from post infection day (PID) 28 in order to have probang samples 
from a minimum of four separate days for determination of carrier status. 
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Small samples of tissue from the dorsal soft palate was collected using a fiberscope (Vet-vu 
2FSb) fitted with cutting biopsy forceps, at three or four time points during the experiments. 
Animals were sedated through intravenous injection of xylazine (Rompun vet© 1.5 ml/ 
animal) and positioned in ventral recumbency. The fiberscope was introduced through one 
nostril and positioned to allow clear visualization of the nasopharynx, with the entrance of the 
trachea in central view. Tissue samples were collected from the ventral surface (constituting 
the dorsal soft palate), just to either side of the mid plane, rostral to the epiglottis. The site of 
sampling is believed to house a high density of diffuse lymphoid tissue, which has been 
corroborated through standard HE staining of randomly selected biopsy samples (Figure 1). 
Two pieces of tissue, approximately 1x1x1 mm in size, were harvested from slightly different 
locations within the sampling area and included in each sample. 
The first biopsy sample from each animal was collected one week prior to inoculation 
(reference sample). The second biopsy was collected during the acute phase of infection, 
defined as the first day when the animals showed a rectal temperature of above 40
o
C (phase 
1), with a third sample being collected 7 days later (phase 2). In the first of the three 
experiments (FMD 2008), animals were kept under observation for a period of 100 days after 
inoculation. In this experiment, final collection of tissue samples from the pharyngeal mucosa 
was carried out through an additional endoscopical examination at PID 28 (phase 3). The 
other two experiments (FMD 2010 a and c) were terminated at PID 31-35 with post mortem 
examinations and collection of additional tissue samples from the dorsal soft palate (DSP) at 
this time point. Tissue samples were stored in RNAlater
TM
 (Qiagen) at 6
o
C overnight, and 
frozen at -20
o
C until further processing.  
Quantitation of virus excretion in probang samples. 
In order to determine the carrier status of individual animals, the level of FMDV RNA in 
probang samples was measured using quantitative RT-PCR assays following a protocol 
described previously
33
. 
Total RNA was extracted using a Magna Pure LC Total Nucleic Acid Isolation Kit (Roche) 
with an automated robotic workstation (Roche) using 200µl of sample, according to the 
manufacturer’s instructions. Each RNA sample was eluted in a volume of 50µl and stored at -
70
o
C until further processing. 
Reverse transcription was carried out using 6µl of extracted RNA in a total volume of 15µl, 
using a TaqMan RT kit with random hexamer primers (Applied Biosystem) at 48
o
 C for 45 
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minutes and 95
o 
C
 
for 5 minutes. 7µl of cDNA was mixed with 18µl of 2x TaqMan universal 
PCR mastermix (Applied Biosystems) containing 10 pmol/µl of FMDV specific forward and 
reverse primers and 5 pmol/µl of fluorescently labeled probe, targeting the 5’UTR region of 
the FMDV genome. PCR amplification was carried out for 50 cycles, in a Model Mx 3005P 
Thermal cycler (Applied Biosystems). Results were analyzed using MxPro software. 
Quantitation of IFN -α/β and TNF-α and mRNAs in tissue samples 
The levels of IFN-α and-β and TNF-α mRNAs were determined using quantitative RT-PCR 
assays , following a protocol described by Zhang et al.
34
. 
Approximately 20mg of tissue sample was homogenized using a fastprep tissue lyser FP120 
(Thermo Electron Corporation BIO 101).  RNA extraction from the lysate was performed 
using the RNeasy mini kit (Qiagen) following the manufacturer’s instructions. Extracted 
RNA was eluted in a final volume of 30µl. 
Reverse transcription of RNA was carried out as described above with the exception that the 
cDNA of samples and standards was diluted 1:5 prior to PCR analysis, with a total volume of 
5µl of diluted template (hence 1µl of undiluted cDNA) being used for each PCR reaction. 
Primers and fluorogenic probes used for the detection of IFN mRNAs have been described 
previously
28
 and were originally designed using multiple sequence alignments of bovine IFN-
α and-β available in Genbank (see Table 2). These assays were designed to detect all of the 
nine known bovine IFN-α gene products or the three known IFN-β gene products. Levels of 
TNF-α and IFN α- and β mRNA were quantified using a fluorogenic probe-based (TaqMan) 
detection system with 1µl of cDNA in a final reaction volume of 25µl. Diluted cDNA was 
mixed with TaqMan Master Mix (Applied Biosystems) containing 22.5 pmol of specific 
forward and reverse primers plus 5 pmol of fluorescently labeled probes specific for each 
gene of interest. PCR amplification was carried out for 50 cycles in a Model Mx 3005 
Thermal cycler as above. Similar analyses were performed for the mRNA encoding the 
housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for each sample.  
Quantitative analysis 
Gene expression was calculated using the comparative Ct method
16. In this method, ΔCt is 
determined by calculating the difference in the measured Ct values of the target and the 
normalizer (GAPDH) within each sample. The pre-inoculation tissue sample was chosen as 
the reference sample for each individual animal. ΔΔCt is defined as the difference in ΔCt 
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between the sample of interest, and the reference sample. Finally, values were transformed 
into absolute values using the formula 2
-ΔΔCt
.  
Statistical analysis 
Prior to analysis, survey data were standardized as relative expression values compared to the 
normalizer (GAPDH) using the method described above. Deviances in survey data from pre-
inoculation values were observed when survey values were different from 1. The data were 
analyzed with a mixed-effects model where time of observation (phase 1, phase 2 or phase 3) 
was included as a fixed effect. Also carrier status, inoculated/contact status and the 
interaction between these were included as fixed effects. Survey number (experiment ID; 
2008, 2010a, or 2010c) was included as a random effect. Due to the standardization, 
individual animal effects were not included in the model.  
In order to stabilize the variance, data were transformed using the natural logarithm prior to 
analysis. The applicability of the models was ensured through standard methods and the 
Kolmogorov-Smirnov test for normality. Model reduction was performed with the likelihood 
ratio method
6
. 
Levels for groups of data points significantly different from 1 were calculated through 
analytical expressions for means of the inverse transformations. Due to the structure of the 
Ln-transformations, confidence intervals were calculated by transforming standard 
confidence interval for transformed data (mean ± 1.96 × standard deviation) with the inverse 
transformation, and taking the smallest interval symmetric around the level that included this 
interval. 
Pre-inoculation data (from the reference samples) were investigated for any effect of carrier 
status through standard 1-sided analysis of variance. 
For TNF-α, the effect of carrier status and inoculated/contact status were also investigated for 
each value of time of observation (i.e. phase 1, phase 2 and phase 3). 
All analyses were carried out using Splus
©
 version 6.1 (Insightful Corp. 2002). 
Results 
During a series of challenge experiments investigating the host response to infection by 
FMDV O UKG 34/2001 in cattle, we have developed a technique for collecting small tissue 
samples consisting of pharyngeal epithelia with subjacent submucosa and diffuse lymphoid 
tissue (see Figure 1) from live animals, using an endoscope fitted with cutting biopsy forceps. 
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In contrast to previous study designs, this novel approach allows for collection of samples of 
pharyngeal mucosa at sequential time points during the course of infection by FMDV.  
Progression of clinical disease 
Characteristics of the observed progression of the clinical infection of cattle by FMDV, 
together with results from measurement of viremia and the development of anti-FMDV 
antibodies has been presented in a separate report
26
. 
In brief, all animals included in the experiments developed mild to moderate clinical signs of 
FMD. Inoculated animals developed clinical signs of FMD at PID 1-2, whilst onset of clinical 
disease in contact animals was observed from PID 2-5. FMDV RNA was detectable in serum 
from all infected animals for a period of three to five days. Anti-FMDV serotype O 
antibodies in serum reached the diagnostic cut-off level at around PID 4 to 5 in inoculated 
animals and at PID 7 to 10 in the contact group (data not shown). Appearance of circulating 
antibodies was accompanied by a rapid reduction in viremia. There were no detectable 
differences in the appearance of the clinical infection, levels of viremia, or the anti-FMDV O 
antibody titres (data not shown), between directly inoculated and contact infected animals, or 
between carriers and non-carriers. 
Prevalence of carriers 
Carrier status was determined on the basis of detection of FMDV RNA genome, using qRT-
PCR, in probang samples at or beyond PID 28
33
. An animal was regarded as being a carrier 
following detection of at least two positive probang samples (Ct value <40), out of a 
minimum of four analyzed samples collected on or after PID 28. 
The prevalence of carriers detected in the three separate experiments was 6/12 (50%), 3/12 
(25%) and 7/12 (58%) respectively (Table 1), with an overall average of 44% (16/36) which 
is consistent with what has been found previously in experimental infections with FMDV 
2,5,19
. A summary of the presence of FMDV RNA in probang samples at different times post-
infection in carriers and non-carriers is shown in Figure 2. The initial profile of virus 
excretion in these samples is very similar but in non-carrier animals complete clearance of 
FMDV RNA occurs by about 20 days post infection (DPI) whereas it is maintained in 
carriers beyond 30 DPI. A more detailed study on the level and duration of virus excretion in 
probang samples has been presented elsewhere
25
. 
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Cytokine mRNA expression in tissue samples from the dorsal soft palate 
Sequential biopsy samples were collected from each animal prior to virus infection, then on 
the first day of acute disease (phase 1) plus 7 days later (phase 2) and finally between 28 and 
35 DPI (phase 3). Relative levels of mRNA expression in these samples encoding IFN-α- 
and-β, and TNF-α were determined using qRT-PCR assays and are presented in Figure 3. A 
significant down-regulation of the expression of IFN-β mRNA was observed in tissue 
samples collected during the acute phase of infection (see Figure 3b, phase 1: relative 
expression of IFN-β = 0.65 +/- 0.25, compared to a baseline-expression (1), level of 
significance: p= 0.02). There was no statistically significant up-or down regulation of the 
levels of IFN-α mRNA observed at any of the measured time points of infection, although the 
observed expression levels for this cytokine mRNA during infection were also below the 
baseline expression measured in the pre-inoculation samples (Figure 3a). 
In contrast to the down-regulation of IFN-β mRNA, the expression of TNF-α mRNA was 
significantly increased during phase 1 (p=0.005) and 3 (p=0.009), although with levels not 
significantly different from baseline values observed at phase 2 (Figure 3c).  
To determine whether the expression of TNF-α mRNA was different between animals which 
were subsequently identified as carriers or not, the expression levels were also compared 
between these two separate groups of animals. The levels of TNF-α mRNA in the biopsy 
samples harvested from animals that were subsequently identified as FMDV-carriers were 
found to be significantly higher when compared to the non-carriers (see Figure 4, relative 
expression levels are presented in Table 3, level of significance: p=0.048). The calculated p-
values did not reach significance when results from these two groups from the three different 
phases of sampling were analyzed separately. The plotted data (Figure 4) does, however, 
indicate a clear trend with higher values in carriers during both acute (phase 1) and persistent 
phases (phase 3) of infection consistent with the overall data presented in Figure 3c. 
 
Discussion 
The characteristics of the clinical infection observed in the experiments included in this study 
were consistent with what has previously been reported for infection with FMDV O UKG 
34/2001 in cattle
1,32
.  
Sequential biopsy samples from the pharyngeal mucosa have been harvested from FMDV 
infected calves at different times after infection and the expression of specific genes related to 
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the host response to infection have been analyzed. This system has significant advantages 
compared to post-mortem analysis since the expression levels of each gene are related to the 
baseline level of each animal individually. Furthermore it was possible to analyze tissue 
samples collected during the early phases of infection, whilst still being able to determine 
whether each FMDV infected animal went on to become a carrier or not. 
A key observation was that the IFN-β mRNA levels in biopsy samples harvested from the 
DSP during acute infection (phase 1) were significantly down-regulated when compared to 
baseline expression (Figure 3b). This observation is consistent with the results from De Los 
Santos et al.
9
 who have previously demonstrated that FMDV is capable of inhibiting the 
induction of IFN-β in cultured porcine kidney cells. By comparing the IFN response induced 
by either a wild type FMDV or the corresponding mutant lacking the leader protease (Lpro), 
it was concluded that the Lpro was responsible for a specific inhibition of IFN-β induction in 
addition to a previously demonstrated general inhibition of host cell protein synthesis
9,12,17
. In 
a subsequent publication, the same group concluded that the observed inhibition of IFN-β 
induction was caused, at least in part, by the degradation of NFкB induced by the FMDV 
Lpro
10
. In addition, it has recently been reported that the Lpro is also responsible for the 
degradation of interferon regulatory factor 3/7 (IRF 3/7) which, in addition to NFкB, is also 
an important factor in the induction of transcription of type 1 IFNs
29
. Observations from the 
current study indicated that the IFN-β mRNA levels in samples harvested during the acute 
phase of infection were significantly below the levels found in the reference samples 
collected prior to inoculation. This could indicate that in addition to inhibition of the IFN 
response that is normally induced by virus infections, FMDV also affects the baseline 
expression of this cytokine. The levels of the measured responses in the biopsy samples used 
for analysis in the current investigation, could, however, be influenced by the fact that these 
samples consist of a combination of different types of cells (see Figure 1). This mixture of 
cell types should not be expected to respond as homogenously to infection with FMDV as 
cultured cell-lines with known susceptibility to the infection.  
No statistically significant changes in the expression of IFN-α were detected in the DSP at 
any stage of FMDV infection in the current studies, although the observed expression levels 
were, for this cytokine, below baseline levels throughout the study period (Figure 3a). It has 
been reported that mRNA levels encoding IFN-α and-β were up-regulated in nasal associated 
lymphoid tissue (NALT) collected from the DSP of animals acutely infected with FMDV O 
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UKG 34/2001, when compared to uninfected control animals
34
.  It should, however, be noted 
that, in a subsequent publication based on a similar experimental set-up it was concluded that 
there was no measurable up-regulation of IFN-α/β or TNF-α mRNA in microdissected 
epithelium from the DSP during the acute phase of infection
31
. These results were based on 
tissue samples obtained from a relatively small number of animals, with 2 and 4 animals 
euthanized during acute infection in the two experiments respectively. The levels of the 
mRNAs in harvested tissue samples were compared to a baseline derived from expression 
levels in one or two un-infected control animals. Our results are based on measurements from 
36 animals, with mRNA levels expressed in relation to the base-line levels determined for 
each animal individually. By basing the statistical analysis on results from analysis of 
samples obtained from a larger number of animals, it should be possible to reduce the 
variance and thereby achieve a more robust model. The system of comparing the expression 
levels to a baseline derived from analysis of pre-inoculation samples from each individual 
animal should also minimize possible effects of individual animal variations in the analysis.   
We have previously reported a consistent peak in the bioactivity of type 1 IFN in sera from 
cattle infected with FMDV serotype O
26
 which occurred at 1 to 5 DPI, coincident with the 
onset of acute disease (phase 1). This finding has been corroborated recently by Reid et al.
22
 
using a similar experimental system.  In relation to the findings of an induction in systemic 
type 1 IFN, it is interesting to note that we observed a down-regulation in the expression of 
IFN-β within the biopsy samples obtained from the DSP during the acute infection, while the 
IFN-α mRNA levels were not significantly altered from base-line levels at any of the time-
points targeted for sampling (Figure 3a-b). As mentioned above, an IFN response can be 
induced both by cells that are directly infected by the virus, as well as by cells of the innate 
immune system which detect common pathogenic features through activation of pattern 
recognizing receptors. The results from our studies indicate that although a clearly 
measurable systemic IFN response was observed, these increased levels of type 1 IFN are not 
derived from cells of the pharyngeal region and hence must be the result of activation of cells 
located elsewhere. As indicated above, porcine plasmacytoid dendritic cells isolated from 
peripheral blood mononuclear cells, can be induced to express IFN by FMDV when it is 
within complexes with IgG but this does not occur with the virus alone
13
. Analogous results 
for bovine large low-density cells from blood and lymph nodes have recently been published 
by Reid et al.
22
. However, it should be noted that the systemic IFN response in cattle, that we 
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have previously reported, occurred very early post-infection and significantly in advance of 
the induction of measurable anti-FMDV antibodies
26
.  
There was an overall increase in mRNA levels of TNF-α during acute (phase 1) and 
persistent (phase 3) stages of infection (Figure 3c). TNF-α is known to be involved in the 
induction of local inflammatory reactions in response to tissue injury or infection. TNF-α 
activation causes an increase in vascular permeability, facilitating the exit of activated cells of 
the immune system from the blood vessels at the site of tissue damage. It is therefore 
reasonable to believe that the presence of any form of infectious agent could result in 
increased levels of TNF-α in the affected tissue.  
The expression levels of TNF-α were significantly higher in animals that were subsequently 
identified as FMDV-carriers compared to the non-carriers. The difference between the two 
groups was most clearly apparent in samples harvested during the persistent phase of 
infection (phase 3) (Figure 4 and Table 3). These results are consistent with and extend what 
has previously been reported by Zhang et al.
34
 since  the results from this previous study were 
based on samples from only 6 animals (2 carriers and 4 non-carriers) whereas our results are 
based on measurements in samples collected from 36 animals (16 carriers and 20 non-
carriers).  
It could be argued that the procedure of harvesting tissue biopsies from live animals could 
possibly results in a provoked inflammatory response within the tissue targeted for sampling. 
It should, however, be noted, that the animals were allowed a period of rest of at least 21 days 
between the samplings performed during phase 2 and phase 3. Minor lesions on mucosal 
surfaces are known to heal within a very short time, and it is therefore unlikely that the 
increased levels of TNF-α that were observed in samples harvested during phase 3 (>28 days 
post infection) within the group of FMDV-carriers would have been caused by the sampling 
procedure in itself. 
We have previously reported that the carrier state in FMDV infection is not associated with a 
sustained systemic inflammatory reaction, based on measurements of the acute phase proteins  
serum amyloid A and haptoglobin combined with the bioactive type 1 IFN in sera of infected 
cattle
26
. The results from measurements of TNF-α mRNA in this study could, however, 
indicate that there could still be a prolonged local inflammatory reaction in the pharyngeal 
region during FMDV persistence.  
There is still a lack of consensus regarding the nature of pathogenesis during persistent 
FMDV-infection in cattle. Some researchers have reported that persistent FMDV is localized 
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in the basal layers of the pharyngeal epithelium
32,36
, whereas others have reported virus 
persistence within germinal centers of lymphoid tissue
15
. Results from the current study, with 
significantly up-regulated levels of TNF-α in the DSP of carrier-animals, could possibly 
support the theory of an active involvement of the pharyngeal region in the persistence of 
FMDV in cattle. We have, however, with the current techniques, only been able to detect low 
levels of FMDV RNA in tissue biopsies from the DSP during acute and persistent infection
25
. 
It is possible that the cytokine response measured in the harvested biopsy samples could be 
influenced by signals from neighbouring cells and may thus react to the local infection 
without being actively infected. Further investigations will be necessary to elucidate the 
relationship between the innate host response to FMDV and the mechanisms involved in the 
pathogenesis of the infection, including the anatomical sites involved in virus replication 
during early and persistent infection. We believe that the newly developed experimental 
procedure, with the possibility of collection of tissue biopsies from live animals during 
different stages of infection, could be useful for further investigations of the host-response to 
FMDV infection in cattle. 
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Table 1 
General features of the three animal experiments included in the study. 
 
 
 
 
 
 
 
 
 
 
 
Table 2 
Primers and probes for bovine IFNs and GAPDH. Primers and probes used for detection of 
the bovine IFNs and GAPDH. Primers and probes used for amplification of IFN-α and-β 
were designed using  alignments of the bovine IFN-α and IFN-β sequences available in 
GenBank (for IFN-α, A00145, A00146, A00147, A00148, X93087, X93088, X93089, 
E00133, E00134, E00135, M11001 and Z46508; for IFN-β,  M15477, M15478, and 
M15479) as previously described by Valarcher et al. (2003). 
 
 
Experiment 
ID 
Number of animals 
(Inoculated: 
Contact) 
Carriers /  
Non-Carriers 
Duration (PID) 
FMD 2008 12 (6:6) 6/6 98 
FMD 2010 a 12 (6:6) 3/9 31 
FMD 2010 c 12 (6:6) 7/5 35 
Target Primer/probe Primer/probe sequence (5’-3’) 
IFN-α FP GTG AGG AAA TAC TTC CAC AGA CTC ACT 
 RP TGA RGA AGA GAA GGC TCT CAT GA 
 Probe TGC TCT GAC AAC CTC CCA GGC ACA 
IFN-β FP CCT GTG CCT GWT TTC ATC ATG A 
 RP GCA AGC TGT AGC TCC TGG AAA G 
 Probe ATG GTT CTC CTG CTG TGT TTC TCC ACC AC 
GAPDH FP GCA TCG TGG AGG GAC TTA TGA 
 RP GGG CCA TCC ACA GTC TTC TG 
 Probe CAC TGT CCA CGC CAT CAC TGC CA 
TNF-α FP CCG GTG GTG GGA CTC GTA T 
 RP GCT GGT TGT CTT CCA GCT TCA 
 Probe CCA ATG CCC TCA TGG CCA ACG 
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Table 3 
Expression levels of TNF-α mRNA in the biopsies harvested from the DSP during acute 
(phase 1), sub-acute (phase 2) and persistent (phase 3) stages of FMDV infection. Relative 
mRNA levels are expressed as fold-increase compared to a baseline value of 1. 
 
 Carrier Non-Carrier 
Phase 1 1.89 (+/- 0.41) 1.47 (+/- 0.26) 
Phase 2 1.28 (+/- 0.20) 1 
Phase 3 1.81 (+/- 0.38) 1.41 (+/- 0.25) 
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Figure 1 
 
 
 
Section from formalin fixed and paraffin wax-embedded biopsy sample from the DSP 
harvested prior to inoculation. This section includes intact non-cornified stratified squamous 
epithelium (a), underlying submucosa (b) and lymphoid tissue (c). bar, 100µm 
 
 
 
 
 
 
 
 
 
 
 
a 
b c 
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Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
FMDV RNA levels detected by qRT-PCR in probang samples harvested from a total number 
of 36 calves during an experimental period of 35 days. In total, 16 animals were detected as 
FMDV carriers, with FMDV RNA detected in a minimum of two samples collected on or 
later than PID 28. In animals that were not detected as carriers of FMDV, virus excretion 
became undetectable by approximately PID 20.   
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Figure 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
mRNA expression levels of a) IFN-α, b) IFN-β and c) TNF-α, in biopsies harvested from the 
DSP of FMDV infected calves (n=36). Samples were collected on the first day of appearance 
of clinical signs of infection (phase 1), seven days after the first sampling (phase 2) and at 28-
35 days post infection (phase 3). Relative expression levels of target mRNAs were calculated 
by comparison to the expression of the housekeeping gene GAPDH within each sample. 
Expression levels for each phase of sampling were related to the baseline expression 
measured in pre-inoculation samples harvested from each individual animal. In order to 
stabilize the variance for the statistical analysis of data, the values have been transformed 
using the natural logarithm so that the baseline-expression levels equal “0” on the y-axis. 
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Figure 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expression levels of TNF-α mRNA in sequentially harvested samples of DSP from FMDV-
carriers and non-carriers at the onset of clinical signs (phase 1), 7 days later (phase 2) and 28-
35  DPI (phase 3).  There was a significant difference in the overall expression levels of TNF-
α mRNA, with higher levels in animals that were eventually identified as FMDV-carriers 
(p=0.048). 
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Abstract 
Foot-and-mouth disease (FMD) is a highly contagious viral infection of significant financial 
importance to the export and trade of agricultural products. The occurrence of persistently 
infected “carriers” of FMD-virus (FMDV) in ruminant species adds further complications to 
disease control. There have been significant discrepancies in reports regarding the 
pathogenesis of FMDV infection in cattle with specific emphasis on the anatomical sites 
involved in early and persistent virus replication. In this study, collection of small biopsy 
samples from the dorsal soft palate (DSP) of live animals was used to investigate the level of 
FMDV RNA present at this site at sequential time points during the  infection. Results were 
compared to measurements of virus excretion in samples of oropharyngeal fluid collected at 
corresponding time points. Possible sites of virus persistence were investigated through 
measurements of the levels of FMDV RNA in the DSP as well as mandibular and 
retropharyngeal lymph nodes beyond 28 days after infection. 
Results indicated only low levels of FMDV RNA present in samples of pharyngeal epithelia 
during both early and persistent phases of infection with significantly higher levels of virus 
detected in pharyngeal excretions. It is concluded that the targeted area for sampling within 
the DSP does not harbour significant levels of virus replication during acute or persistent 
FMDV infection in cattle. Furthermore, the DSP and the mandibular and retropharyngeal 
lymphnodes cannot be concluded to be principal sites for persistence of FMDV. 
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Introduction 
Foot-and-mouth disease (FMD) is a highly contagious viral infection which affects cloven-
hoofed animals including cattle, pigs and sheep
1
. The disease spreads rapidly amongst 
susceptible animals, with devastating consequences for farmers and agricultural industries in 
affected areas. 
Foot-and-mouth disease virus (FMDV) is a non-enveloped, positive stranded RNA virus 
belonging to the Aphthovirus genus of the picornavirus family
9
. The clinical disease is 
manifested by development of vesicular lesions in areas covered by cornified stratified 
squamous epithelia such as the oral cavity and coronary bands, causing excessive salivation, 
inappetence and lameness. Infected animals develop transient viremia lasting for about 2-4 
days, which is effectively counteracted by the development of circulating anti-FMDV 
antibodies. Disease severity varies greatly between different virus isolates, as well as between 
different host species, with pigs developing the most severe clinical signs, followed by cattle 
with mild to moderate clinical disease, and sheep in which the infection may sometimes go 
unnoticed
1
. Mortality rates are generally very low in adult animals, whereas juvenile animals 
may develop fatal myocarditis as a consequence of the infection. The clinical course of the 
disease is usually over within 14 days after infection, but the occurrence of persistently 
infected, so called “carrier-animals” within ruminant species causes further complications for 
disease control. FMDV carriers are defined as animals with infectious FMDV in 
oropharyngeal fluid  more than 28 days post infection
28
. In practice, the level of FMDV in the 
oropharyngeal fluid is normally low and detection is intermittent. It has previously been 
demonstrated that analysis of samples of oropharyngeal fluid using specific qRT-PCR, is  
suitable for detection of FMDV-carriers in experimentally infected animals
26
. Development 
of the carrier state is unaffected by the presence of neutralizing antibodies in the circulation 
following vaccination or previous exposure to the virus, and thus vaccinated animals may 
become carriers of FMDV without the pre-occurrence of clinical disease
12,15,23
. 
FMD pathogenesis has been studied in detail by several research groups. The initial site of 
FMDV replication in cattle has been suggested to be located within epithelia and lymphoid 
associated tissues of the pharyngeal area
2,5,13,18,20
 or alternatively, within the lungs 
6,10,11
.  
An experimental study of the early pathogenesis of FMDV in cattle performed by Pacheco et 
al
20
 showed that FMDV RNA could be isolated from tissue samples from both the upper and 
lower respiratory tracts at 24 hours post aerosol exposure to serotype O FMDV. It was 
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proposed that FMDV could reach the lower respiratory tract following aerosol exposure but 
that the pulmonary tissues were only poorly permissive for FMDV replication whilst primary 
virus replication was found within respiratory-associated lymphoid tissues of the upper 
airways
20
. Subsequently the same group defined the initial site of viral replication as being 
located within the epithelial cells overlying the lymphoid crypts of the pharyngeal mucosa
7
. 
Thus, it was proposed that primary replication of FMDV in cattle occurs in pharyngeal 
epithelia with subsequent widespread FMDV replication within pulmonary pneumocysts 
accompanied by a significant decrease in viral load within pharyngeal tissues. In contrast to 
these recent findings, previous work of other authors have failed to  find  evidence of 
significant FMDV replication within the lungs
,2,5,13
. Thus, there is still no clear consensus 
regarding the early pathogenesis of FMD and comparison of published results is confounded 
by variations in experimental design with the use of different virus strains plus varying routes 
of administration of the virus. 
With regard to the localization of persistent FMDV in carrier animals the published results 
are somewhat more consistent; generally suggesting that the  virus shed in oropharyngeal 
fluid originates from within tissues of the pharyngeal region
4,5,12,17,21,27,30
. There are, however, 
some differences regarding what is believed to be the exact anatomical localization of 
persistent virus. Some  have suggested that FMDV persists at a low level of replication within 
pharyngeal epithelial cells
12,26,30
, whilst others have reported that persistent FMDV is found 
as intact, but largely quiescent, viral particles within lymphoid tissues of the pharynx
17
.  
In this study, endoscopical collection of small tissue samples from the pharyngeal mucosa 
from live animals was used to investigate the sites of virus replication in cattle with FMD. 
Biopsy samples from this specific anatomical region were collected from the same animals at 
sequential time points; prior to inoculation, during the acute phase of infection with serotype 
O FMDV and subsequently. The presence of FMDV RNA in these biopsy samples and 
concurrent viral shedding in oropharyngeal fluid were determined. Other possible sites of 
viral persistence were investigated through analysis of samples collected post mortem. 
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Materials and Methods 
Animal experiments and samples 
Animal experiments were performed in biosecure research facilities at DTU-Vet, Lindholm 
Island, Denmark, in accordance with the requirements of the Danish Animal Experiments 
Inspectorate (License 2003/561-742; 2008/561-1541). Three independently performed 
experiments, using a similar experimental set up, were included in this study (see Table 1).  
Each of the experiments included 12 steers (4-5 months old) of mixed-holstein breed. The 
general experimental protocols have been described in detail elsewhere
25
. In brief, six 
animals in each experiment were inoculated with FMD O UKG 34/2001 (original inoculum 
obtained from IAH-Pirbright (UK), and then passaged once in cattle) using subepidermo-
lingual injection, each animal receiving approximately 10
6.9
 TCID50 in a volume of 0.5 ml.  
Six other animals were kept in continuous direct contact with the inoculated animals, with 
two inoculated plus two contact animals in each pen and with the stable facilities also 
allowing direct contact between animals in separate pens. 
All animals were monitored daily, with measurements of rectal temperature and observation 
of clinical signs. Serum samples were collected daily from 3 days prior to inoculation and 
throughout the first two weeks of the experiments but then on a weekly basis throughout the 
remaining part of the experiment.   
Samples of oropharyngeal fluid (probang samples) were collected, for the quantification of 
viral shedding, as well as determining the carrier status of individual animals. These samples 
were obtained prior to inoculation, once daily during the first week after inoculation, then 
every other day throughout the second week and on a weekly basis subsequently. Additional 
samples were collected after post infection day (PID) 28 in order to have probang samples 
from a minimum of four separate days for determination of carrier status. 
 A recently developed technique for endoscopical collection of biopsy samples from the 
pharyngeal region of live animals was used in order to obtain sequential tissue samples from 
the dorsal soft palate from the infected animals. The method used for sampling has been 
described in detail elsewhere
24
. 
In brief, small samples of tissue from the dorsal soft palate was collected using a fiberscope 
(Vet-vu 2FSb) fitted with cutting biopsy forceps, from sedated animals at three time points 
during the experiments. Tissue samples were collected from the caudal end of the dorsal soft 
palate, at a site which has previously been proven to house a high density of diffuse lymphoid 
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tissue
24
. Two pieces of tissue, approximately 1x1x1 mm in size, were harvested from slightly 
different locations within the sampling area and included in each sample. 
The first biopsy sample from each animal was collected one week prior to inoculation. The 
second biopsy was collected during the acute phase of infection, defined as the first day when 
the animals showed a rectal temperature of above 40
o
C, with a third sample being collected 7 
days later. In the first of the three experiments (FMD 2008), animals were kept for 
observation for a period of 100 days after inoculation. In this experiment, final collection of 
tissue samples from the pharyngeal mucosa was carried out through an additional 
endoscopical examination at PID 28. Lymphnodes from post mortem examinations of the 12 
animals included in this experiment were not included in the analysis. The other two 
experiments (FMD 2010 a and c) were terminated at PID 31-35 with post mortem 
examinations and collection of mandibular and retropharyngeal lymphnodes A section of 
approximately 2-3 mm thickness was cut perpendicular to the longitudinal axis of the 
harvested lymph nodes and several small tissue samples of approximately 1x1x1 mm were 
collected from the lymphoid cortex of each lymph node. Post mortem samples of pharyngeal 
mucosa were harvested from the dorsal soft palate from the anatomical region that had 
previously been targeted during the endoscopical sampling procedure. All tissue samples 
were stored in RNAlater
TM
 (Qiagen) at 6
o
C overnight, and frozen at -20
o
C until further 
processing.  
Quantitation of viremia and virus excretion in probang samples 
The level of FMDV RNA in serum and probang samples was determined using quantitative 
RT-PCR assays  following a protocol described previously
26
. 
Total RNA was extracted using a Magna Pure LC Total Nucleic Acid Isolation Kit (Roche) 
with an automated robotic workstation (Roche) using 200µl of sample, according to the 
manufacturer’s instructions. Each RNA sample was eluted in a volume of 50µl and stored at -
70
o
C until further processing. 
Reverse transcription of FMDV RNA was carried out using 6µl of extracted RNA in a total 
volume of 15µl, using a TaqMan RT kit with random hexamer primers (Applied Biosystem) 
at 48
o
 C for 45 minutes and 95
o 
C
 
for 5 minutes. 7µl of cDNA was mixed with 18µl of 2x 
TaqMan universal PCR mastermix (Applied Biosystems) containing 10 pmol/µl of forward 
and reverse primers and 5 pmol/µl of fluorescently labeled probe, targeting the 5’UTR region 
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of the FMDV genome. PCR amplification was carried out for 50 cycles, in a Model Mx 
3005P Thermal cycler. Results were analyzed using MxPro software. 
Quantification of FMDV in tissue samples 
Approximately 20mg of tissue sample was homogenized using a Fastprep tissue lyser FP120 
(Thermo Electron Corporation BIO 101).  RNA extraction from the lysate was performed 
using the RNeasy mini kit (Qiagen) following the manufacturer’s instructions. Extracted 
RNA was eluted in a final volume of 30µl. 
Reverse transcription of RNA and qRT-PCR was carried out following the protocol described 
above with the exception that the cDNA of samples and standards was diluted 1:5 prior to 
PCR analysis, with a total volume of 5µl of diluted template (hence 1µl of undiluted cDNA) 
being used for each PCR reaction. 
Each sample was analyzed for the presence of FMDV RNA using two different sets of 
primers and fluorogenic probes. One assay targeted the 5’UTR region22 whilst the other 
targeted the 3D protein coding region
14
. Both assays used were previously validated and 
accredited for FMDV diagnostics according to the quality assurance system of DTU-Vet. In 
addition, quantification of the mRNA corresponding to the housekeeping gene 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was performed  for each sample
28
 in 
order to ensure a consistent amount of template in the samples. 
Quantification of anti-FMDV Antibodies using a solid phase blocking ELISA 
Serum concentrations of FMD specific antibodies were measured using a serotype-specific 
solid phase blocking ELISA
8
. In brief, microtitre plates were coated using guinea-pig 
immune sera raised against FMDV O Manissa before addition of inactivated FMDV antigen. 
Samples of the bovine sera were added, incubated overnight and then rabbit anti-FMDV 
serotype O serum was added and the bound antibodies were detected using horseradish-
peroxidase conjugated porcine anti-rabbit IgG. All serum samples were initially screened at a 
dilution of 1:5 and positive samples (blocking percentage >50%) were analyzed in a two-fold 
titration starting at a dilution of 1:10 to allow determination of antibody titers. 
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Results 
Progression of clinical disease 
All animals included in the three experiments developed mild to moderate clinical signs of 
FMD, with an increase in body temperature (Figure 1a) and vesicular lesions in the oral 
cavity being the most prominent findings occurring in all individuals. Less than half of the 
animals developed vesicular lesions on the feet and only two individuals (out of 36) 
developed clearly visible lameness. Inoculated animals developed clinical signs of FMD at 
PID 1-2, whilst onset of clinical disease in contact animals was observed from PID 2-5. The 
animals showed no apparent loss in appetite and all animals recovered from clinical disease 
within approximately seven days, without further complications, and without the need of 
supportive medical treatment. 
Viremia and development of circulating antibodies 
FMDV RNA was detectable in serum from all infected animals for a period of four to seven 
days (Figure 1b). Inoculated animals showed significant viremia at PID 1, reflecting the very 
rapid replication and systemic spread of FMDV.  Anti-FMDV serotype O antibodies in serum 
reached the diagnostic cut-off level at around PID 4 to 5 in inoculated animals and at PID 7 to 
10 in the contact group (Figure 1c). Appearance of circulating antibodies was accompanied 
by a rapid reduction in viremia. There were no detectable differences in the level of viremia, 
(presented as the number of copies of FMDV genome per µl of serum), or the anti-FMDV O 
antibody titres (data not shown), between directly inoculated and contact infected animals, or 
between carriers and non-carriers. 
 Prevalence of Carriers 
Carrier status was determined on the basis of detection of FMDV RNA genome, using qRT-
PCR, in probang samples beyond PID 28. An animal was regarded as being a carrier 
following detection of at least two positive probang samples (Ct value < 40), out of a 
minimum of four analyzed samples collected on or after PID 28
27
. 
The prevalence of carriers detected in the three separate experiments was 6/12 (50%),  3/12 
(25%) and 7/12 (58%) respectively in the three different experiments (Table 1), with an 
overall average of 44% (16/36) which is consistent with what has been found previously in 
experimental infections with FMDV
1,5,19
. 
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Detection of FMDV genome using qRT-PCR analysis of tissue and probang samples 
The presence of FMDV RNA in probang and tissue samples, as determined from qRT-PCR 
analysis, is presented for each separate experiment in Tables 2A-C. Due to technical 
problems with the equipment used for sampling, there are a few samples missing at different 
time points in two of the experiments (indicated as “NA” in Table 2 A and B). 
In biopsy samples of pharyngeal mucosa, collected through endoscopical examination during 
the acute phase of infection, FMDV RNA was only detected in 13 out of a total of 34 samples 
analyzed (38%). At the subsequent sampling, performed 7 days after initial detection of 
clinical disease, 8 out of a total of 28 samples (29%) were found positive with either, or both, 
of the two assays used for analysis. In tissue samples derived from the final sampling at post 
mortem examinations (experiments FMD 2010 a + c; at PID 31-35), or endoscopical 
examination (experiment FMD 2008; PID 28) the prevalence of positive samples was 5 out of 
36 (14%). For animals detected as FMDV-carriers, the prevalence of FMDV-RNA positive 
samples of pharyngeal mucosa at PID 28-35 was 31% (5 out of 16 animals). 
In tissue samples of the mandibular and retropharyngeal lymph nodes collected at PID 32-35, 
the prevalence of FMDV-positive samples was 25% (6 out of 24) and 17% (4 out of 24) 
respectively. For carrier animals, these tissues were positive in 4 out of 10 (40%) animals for 
both of the lymph nodes. 
The Ct values in FMDV-positive samples were generally very high for both assays, indicative 
of low levels of FMDV RNA, with some samples having Ct-values above 40 (presented in 
brackets in Table 2 A-C). Positive controls included in the assays were found within the 
normal range accepted for the diagnostic assays. The level of mRNA derived from the 
housekeeping gene GAPDH was at a rather consistent detection level in all samples, with Ct-
values within the range of 22 to 25 cycles. 
For probang samples collected at similar times as the samples of pharyngeal mucosa, the 
prevalence of FMDV RNA positive samples was 100% during the acute phase of infection, 
whilst only 38% of the corresponding tissue samples were found positive. At the second 
phase of biopsy collection, which was performed 7 days after onset of clinical disease, 50% 
of probang samples, and 29% of tissue samples were found positive for FMDV. At the final 
stage of sampling (PID 28-35), 44% of probang samples were positive whilst FMDV could 
only be detected in 14% of the collected tissue samples (Table 2 A-C, Figure 2A). A 
summary of the level of FMDV RNA in probang and DSP biopsy samples that were found 
positive at the different stages of infection is shown in Figure 2B. This indicates that even in 
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the small proportion of DSP samples (see Figure 2A) which did contain detectable FMDV 
RNA at the final sampling stage, the levels were low. It is apparent that throughout the time 
course of infection, the proportion of animals containing FMDV RNA in the biopsy samples 
from the DSP (or from lymph nodes) was much lower than the proportion of animals which 
were excreting FMDV in probang samples (Figure 2A). 
In animals which did not become carriers, it was found that the presence of FMDV RNA in 
probang samples was lost by PID 14 or earlier (Tables 3 A-C, Figure 3).  However, at the 
earlier stages of infection no difference in the level of FMDV RNA was apparent in the 
probang samples from the animals which became carriers and those which did not (Figure 3). 
 
Discussion 
The pharyngeal mucosa is believed to be an important site for FMDV replication during both 
acute
2,13,18 
 and persistent stages of infection
30
. In the current study, sequential collection of 
biopsy samples from pharyngeal epithelia and subjacent mucosa within the dorsal soft palate 
(DSP) of live animals was used to investigate possible sites of virus replication and 
persistence following infection of cattle with FMDV serotype O. The study-design allowed 
for comparison of possible differences between animals that would subsequently develop into 
FMDV carriers and those that would not. The original idea was to harvest biopsy samples, 
which would enable monitoring of the progression of infection within individual animals, 
with minimal interference to the natural course of infection  
The average prevalence of animals detected as FMDV carriers was 44% in the three 
experiments. Results of the FMDV qRT-PCR analysis of the probang samples showed a 
consistent pattern of positive samples in carrier animals, whilst the samples from non-carriers 
became negative at around PID 14 (Tables 3 A-C, Figure 3) and stayed negative throughout 
the remaining parts of the experimental periods. 
The prevalence of FMDV RNA in the DSP during both acute (38%) and sub-acute (29%) 
phases of infection (Tables 2 A,B,C) was much lower than the presence of FMDV in the 
probang samples collected at the same time points which reached 100% in the acute phase of 
infection, and then declined to 50%  by 7 days later (Figure 2). Low quantities and prevalence 
of FMDV RNA were also found in samples of the DSP (14%), as well as mandibular (25%) 
and retropharyngeal (17%) lymph nodes collected at PID 28-35.  
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Quantification of the mRNA levels from the housekeeping gene GAPDH using qRT-PCR 
analysis indicated that the biopsy samples could be used to provide RNA in the consistent 
yield and quality needed for these analyses. Immunohistochemical staining of randomly 
selected biopsy samples showed that they contained intact epithelia with subjacent mucosa, 
as well as diffuse lymphoid tissue as expected
24
.  
The low level and prevalence of FMDV RNA that was detected in the biopsy samples 
suggested that the principal site of FMDV replication is not located within the area of the 
DSP targeted during sampling. With the limited size of the collected tissue samples, it could 
be argued that an uneven distribution of FMDV replication within the DSP could easily be 
missed, and hence, interpreted as “false negative” results. However, taking into account the 
number of samples analyzed in this study it would, even assuming a patchy distribution of 
viral replication, be expected to find some samples with a very high content of virus whilst 
other samples could be negative. The levels of FMDV RNA detected within positive tissue 
samples were always very low (Ct values of 35-45), whilst the assays showed significantly 
higher levels and prevalence of FMDV RNA within the probang samples. 
Even though the DSP has been identified previously as the site of virus persistence in FMDV 
carriers
30
, other studies have failed in finding persistent virus in pharyngeal epithelia
17
. 
Furthermore, in the recent study by Juleff et al.
17
, laser capture microdissection, in 
combination with qRT-PCR, determined the site of persistent FMDV to be  within germinal 
centers of lymphoid tissue within the pharyngeal region, with the highest amounts of virus 
RNA, obtained at PID 29-34, found in the mandibular lymph node. Indeed, FMDV RNA was 
found to persist within the germinal centers of this specific lymph node even in animals that 
did not excrete FMDV in oropharyngeal scrapings. It was thus concluded that FMDV may 
persist to some degree in all animals following infection, regardless of whether they can be 
detected as FMDV carriers
17
. In the current study, we found relatively low numbers of biopsy 
samples which were positive for FMDV RNA which were derived from the dorsal soft palate 
or in tissue samples from mandibular and retropharyngeal lymph nodes at PID 28-35. This 
was the case even though a substantial proportion of the cattle (44%) were excreting clearly 
detectable amounts of FMDV in oropharyngeal scrapings at the time of biopsy sampling. It is 
noteworthy that it was not possible to detect convincing amounts of FMDV RNA in any of 
the tissue samples derived from animals that did not excrete FMDV in probang samples. 
Animals included in this study were infected either through direct inoculation in the tongue, 
or through continuous direct contact with inoculated animals. This method has previously 
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been used in numerous experimental studies of FMD in cattle
3,26,29
. There were no observed 
differences in severity or nature of the clinical infection between animals infected through 
direct inoculation or contact exposure. It is however, reasonable to believe that the route of 
initial exposure to the virus could have a significant influence on the site of primary 
replication. In this study, we have found that there was no effect of the route of virus 
exposure on the prevalence of FMDV-RNA positive samples in the DSP or lymph nodes. 
Arzt et al.
7
 used qRT-PCR, in combination with immunohistochemistry and virus isolation in 
cell culture, to investigate the early pathogenesis of FMDV in cattle following aerosol 
exposure. It was concluded that widespread replication of FMDV took place within 
pulmonary tissue following an initial phase of replication within the pharyngeal epithelia. It 
has previously been concluded that the size of particles generated during aerosol exposure 
will influence the site of deposition within the respiratory tract, and hence the possible sites 
of viral entry
5
. Other studies have concluded that aerosol exposure, with deposition of 
artificially produced small droplets of virus inoculum in the lungs, will lead to virus uptake 
and entry through the pulmonary circulation, with subsequent virus replication at distant 
predilection sites
16
.  
It would be relevant to investigate further the involvement of the lungs as a site of uptake and 
primary replication of FMDV in cattle infected by other routes of exposure, most importantly 
in animals infected through direct contact with infected animals. Furthermore, it can be 
discussed whether it is appropriate  to conclude that  virus replication occurs within a specific 
tissue following just detection of FMDV RNA or isolation of infectious  virus since high 
levels of viremia occur. Specific detection of negative strand FMDV RNA, which is only 
present within cells in which virus replication is taking place, should make it possible to 
determine if the virus is actively replicating within the sampled tissues.   
The exact micro-anatomical compartments included in the tissue samples analyzed in this 
study have not been subjected to stringent control. It would however, be expected that 
germinal centers would be included in the majority of samples derived from the mandibular 
and retropharyngeal lymph nodes, as well as in a large proportion of samples derived from 
the dorsal soft palate (as supported by immunohistochemical staining
24
). For future 
investigations, the technique of endoscopical collection of tissue samples from live animals 
could be further developed in order to target different anatomical regions such as pharyngeal 
and palatine tonsils as well as epithelia from the lower respiratory tract.  
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Table 1. 
General features of the three animal experiments included in the study. 
 
 
 
 
 
 
Table 2 (A, B, C) 
Results of qRT-PCR analysis for FMDV RNA in tissue samples from the dorsal soft palate 
(DSP), lymph nodes and probang samples from cattle infected with FMDV O UKG 34/2001. 
 
12 animals were included in each experiment, of which 6 were directly inoculated (nos. 1, 2, 
5, 6, 9, 10) and 6 were contact- infected (nos. 3, 4, 7, 8, 11, 12). Times of sampling: (1) the 
acute phase of infection defined as the first day where animals showed a temperature > 40
o
C; 
(2) seven days after the first sampling (3) PID 28-35. Ct values: +++ <20; ++ 20<30; + 
30<40; (+)>40, Ct values for the mRNA expressed from the housekeeping gene GAPDH 
were within the range of 22-25 Ct for all analyzed tissue samples. 
Experiment 
ID 
Number of animals 
(inoculated: 
contact) 
Carriers/non-
carriers 
Duration (days) 
FMD 2008 12 (6:6) 6/6 98 
FMD 2010a 12 (6:6) 3/9 31 
FMD 2010c 12 (6:6) 7/5 35 
A) FMD 2008 
1 
Acute phase  Animal ID 
sample assay 1 2 3 4 5 6 7 8 9 10 11 12 
probang 5’UTR ++ ++ ++ +++ ++ ++ ++ ++ ++ ++ ++ ++ 
DSP 5’UTR - - - - - NA - - NA - - - 
 3D - - - - - NA - - NA - - - 
2 
Acute phase +7  Animal ID 
sample assay 1 2 3 4 5 6 7 8 9 10 11 12 
probang 5’UTR - - + + - - - - - - + + 
DSP 5’UTR - - (+) + - NA - - NA - (+) - 
 3D - - + + - NA - - NA + - - 
3              
PID28  Animal ID (FMDV carriers marked with*) 
sample assay 1* 2 3 4* 5* 6* 7 8 9* 10 11 12* 
probang 5’UTR + - - + + + - - + - - + 
DSP 5’UTR - - - - + - - - - - - + 
 3D - - - - + - - - - - - + 
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B) FMDV 2010a   
1   
Acute phase  Animal ID 
sample assay 1 2 3 4 5 6 7 8 9 10 11 12 
probang 5’UTR +++ ++ ++ ++ ++ ++ ++ ++ +++ ++ ++ +++ 
DSP 5’UTR (+) (+) - (+) - - - - (+) - - - 
 3D + - - - - - - - - - - - 
2 
Acute phase + 7  Animal ID 
sample assay 1 2 3 4 5 6 7 8 9 10 11 12 
probang 5’UTR - - + (+) + + - - + + + + 
DSP 5’UTR - - NA NA - - NA NA - - NA NA 
 3D - - NA NA - - NA NA - - NA NA 
3              
PID 31  Animal ID (FMDV carriers marked with *)   
sample assay 1 2* 3 4 5 6 7 8 9 10 11* 12* 
probang 5’UTR - + - - - - - - - - + ++ 
DSP 5’UTR - - - - - - - - - - - - 
 3D - + - - - - - - - - - - 
Mandibular ln. 5’UTR - - - - + - - - - - - + 
 3D - - - - - - - - - - - - 
Retropharyngeal ln. 5’UTR - - - - - - - - - - - - 
 3D - - - - - - - - - - - - 
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C) FMD 2010 c   
1.   
Acute phase  Animal 
sample assay 1 2 3 4 5 6 7 8 9 10 11 12 
probang 5’UTR +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ 
DSP 5’UTR (+) - + (+) - - + - - - - + 
 3D - + - - - - + - - - - - 
2. 
Acute phase +7  Animal 
sample assay 1 2 3 4 5 6 7 8 9 10 11 12 
probang 5’UTR - + + + - - - + - + + - 
DSP 5’UTR (+) - - (+) - - - - - - (+) - 
 3D - - - - - - - - - - - + 
3.              
PID 35  Animal 
sample assay 1* 2* 3* 4* 5 6 7 8 9* 10 11* 12* 
probang 5’UTR ++ + ++ ++ - - - - + - + + 
DSP 5’UTR + - (+) - - - - - - - - - 
 3D + - - - - - - - - - - - 
Mandibular ln 5’UTR (+) - - (+) - (+) - - - - - - 
 3D - - + + - - - - - - - - 
Retropharyngeal ln. 5’UTR - - (+) + - - - - - - - (+) 
 3D + - + + - - - - - - - - 
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Table 3 (A, B, C) 
Ct-values from qRT-PCR analysis for FMDV RNA in probang samples collected from three 
separate experiments.  
FMDV carriers were defined as animals with positive detection (Ct<40) in probang samples 
collected on at least two separate days from PID 28 and after (Ct-values included in 
determination of carrier-status are marked in separate boxes in tables). 
 
 
 
**Animal number 1 in experiment FMD 2008 (Table 4A) was euthanized at PID 28 due to 
reasons unrelated to the experiment. The definition of this animal as an FMDV carrier was 
confirmed by virus isolation in primary bovine thyroid cell culture from the probang sample 
collected at PID 28. 
 
A) FMD 2008 
 Animal ID (FMDV carriers marked with *) 
PID 1** 2 3 4* 5* 6* 7 8 9* 10 11 12* 
0  - -  -  -  -   - -  -  -  -  -   - 
1 24.5 40.4 - -  35.2 37.3  - 19.4 35.0 27.8 23.9 36.8 
2 37.5 37.6 - 18.9 31.8 31.7 22.9 22.2 35.3 34.9 35.5 22.1 
3 20.2 31.5 28.6 26.6 19.2 27.2 35.0 24.7 33.2 - 29.0 29.3 
4 22.7 25.5 18.9 24.3 34.0 30.3 28.7 26.0 32.6 32.0 23.8 24.4 
5 37.7 36.4 25.5 28.4 40.3 34.7 24.1 26.4 37.6 36.3 21.8 26.3 
7 32.9 33.9 26.7 30.7 39.8 37.0 31.1 30.8 -   -  - -  
11  -  - 38.5 42.3 -  -  -  -  - - 44.6 42.7 
14  -  -  -  - 43.3 - -  -  -  - -  49.9 
21  -  -  - 36.2 34.2 37.7  -  - 37.2  -  -  - 
28 34.8  -  - 33.7 44.3 38.4  -  - 34.2  -  - 37.5 
35 NA  -  - 33.0 34.5 37.1  -  - 41.4  -  - 37.2 
42 NA  -  - 34.2 42.3 40.1  -  - 36.4  -  - 38.6 
49 NA  -  -  - 44.0 42.5  -  - 38.6  -  - 33.3 
56 NA  -  - 42.2 -  -  -  - 38.4  -  -  - 
63 NA  -  -  - 42.5 38.1  -  - 37.6  -  - 40.6 
70 NA  -  - 33.7 39.4 38.6  -  - 37.2  -  - 38.1 
72 NA  -  - 39.9 38.6 -  -  - -  -  - 42.8 
78 NA  -  - 37.1 38.8 38.4  -  - 42.8  -  - 41.5 
91 NA  -  - 34.7 43.5 38.2  -  - 38.3  -  - 34.8 
98 NA  -  - 34.6  - 40.9  -  - 39.5  -  - 39.5 
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B) FMD 2010 a           
 Animal ID (FMDV carriers marked with *)    
PID 1 2* 3 4 5 6 7 8 9 10 11* 12* 
0 - - - - - - - - - - - - 
1 18.4 27.7 - - - 46.8 - - 14.4 44.6 - - 
2 37.9 28.5 44.3 - 22.1 20.9 - - 37.65 38.2 - - 
4 34.9 - 21.5 20.1 37.1 - - - 38.1 25.9 41.5 - 
7 - - 41.2 42.0 40.3 33.3 24.4 26.0 - - 23.8 17.8 
11 38.6 - 36.8 - - - 32.3 - - 34.0 - - 
14 - 37.6 - 43.3 - - - - - 39.7 33.0 38.7 
21 - 36.7 - - - - 40.0 - - - 31.6 30.3 
28 - 39.3 - - - - - - - - 37.8 - 
29 - 41.0 - - - - - - - 40.4 - 35.5 
30 - - - - - - - - - - 38.7 - 
31 - 39.1 - - - - - - - - - 29.2 
C) FMD 2010 c        
 Animal ID (FMDV carriers marked with *)     
PID 1* 2* 3* 4* 5 6 7 8 9* 10 11* 12* 
0 -  -  -  -  -  -  -  -  -  -  -  -  
1 26.4 31.1  - -  37.7 43.7 -  - 39.5 20.9  - - 
2 36.8 19.0  - 26.7 28.4 18.3 44.1 - 16.9 26.2 43.2 - 
4 - 25.5 23.5 23.7 23.2 26.7 16.6 14.0 30.5 33.3 16.7 22.8 
7 - 30.6 30.5 27.8 37.2 - 30.4 29.1 - 40.0 32.4 24.0 
11 38.0 37.9 - - - - - 37.3 36.2 - 31.7 - 
14 38.3 31.7 - - - - 35.7 38.9 33.3 - 40.2 35.4 
21 - 29.3 - 29.5 - - - - 30.3 - 34.9 37.0 
28 - 28.9 25.1 27.8 - - - - 27.3 - 35.9 33.1 
29 34.3 28.7 30.0 28.1 - - - - 25.9 - 32.1 30.0 
30 33.8 32.8 40.1 32.2 - - - - 31.9 - 33.4 29.3 
31 34.3 34.6 33.6 - - - - - 34.2 - 34.0 29.3 
32 25.8 29.9 28.9 28.1 - - - - 28.7 - 28.0 27.9 
35 28.6 37.2 28.4 29.4 - - - - 32.8 - 31.4 33.7 
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Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characterization of clinical signs in FMDV-infected cattle. Infection parameters. The results 
shown are the mean values (+/- S.E.M) for the indicated parameters from three separate 
experiments each including 12 cattle (6 inoculated with FMDV and 6 in-contact). A) 
Temperature and timing of occurrence of clinical lesions B) Viremia measured by qRT-PCR 
and expressed as copies of FMDV genome/ µl of serum C) anti-FMDV (type O) antibodies in 
serum expressed as blocking percentage derived from a solid phase blocking ELISA. 
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Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) Prevalence of probang samples and tissues samples harvested from the DSP containing 
detectable levels of FMDV RNA at three time points during infection. Number of animals 
included: 36 (probang samples, in each phase), 34 (DSP phase 1), 28 (DSP phase 2) and 36 
(DSP phase 3). 
(B) Levels of FMDV RNA in probang samples and DSP tissue samples that were found 
positive (mean +/- SEM). The presented values are calculated as the 50-Ct value from the 
qRT-PCR assay targeting the 5UTR region of the FMDV genome. Phase 1= the first day the 
animal showed clinical signs of infection, Phase 2= 7 days later, Phase 3 = PID 28-35. 
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Figure 3 
 
 
 
 
 
 
 
 
 
 
 
 
Levels of FMDV RNA in probang samples at three time points during infection in animals 
detected as FMDV carriers versus non-carriers (mean +/- SEM of 50-Ct for the FMDV 
5’UTR qRT-PCR assay). Number of animals: 16 (carriers) and 20 (non-carriers). 
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4. General discussion and conclusions. 
The overall aim of the project included in this thesis has been to investigate the innate host 
response to FMDV infection in cattle. An additional focus has been to elucidate possible 
variations in host response between animals that developed into persistently infected carriers 
of the virus and those that did not.  
The project has involved the performance of seven animal experiments, which have all been 
performed within the Biosafety Level (BSL) 3+Ag stable facilities at DTU-Vet, Lindholm. A 
novel technique of endoscopical collection of small tissue biopsies from the pharyngeal 
region of live animals has been developed and implemented in order to investigate the local 
tissue response to FMDV infection in this specific anatomical region. Manuscripts for 
publication have been based on results from investigations of both the systemic (manuscript 
1) and local (manuscript 2) host response to infection, as well as investigations of FMDV-
pathogenesis through analyses of sites of virus replication and persistence (manuscript 3). 
The first manuscript was based on results from three separate cattle experiments (FMD 3C 
2008, FMD 5C 2010 and FMS 6C 2010). As the latter of these three experiments was 
terminated after 14 days due to technical circumstances, the carrier-status of individual 
animals was only known for the two earlier experiments (24 out of 36 infected animals 
included in the study).  
The investigation included measurements of the acute phase proteins SAA and HP, as well as 
measurements of the bioactivity of type 1 IFNs in sera of FMDV-infected calves, compared 
to un-infected age-matched controls. Results indicated a clear and consistent acute phase 
response in all measured parameters, which was closely correlated in timing to the onset of 
clinical disease and the development of viremia. Statistical analysis of data indicated a 
significantly different HP-response in animals that did not develop into FMDV- carriers 
compared to those that did. The HP-response was determined through calculations of the area 
under the curve (AUC) of serum HP-concentration during a 21 days test period. The plotted 
data indicated that the larger values of the AUC in the non-carriers could be the consequence 
of a slightly slower rate of decline in serum HP concentrations in this group of animals, 
which were effective in clearing the infection. This possible finding will, however, need to be 
confirmed through further investigation with measurements of the HP response in sera from a 
larger number of FMD infected animals with known carrier-status. 
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In this first manuscript, it was further concluded that there was no measurable systemic 
inflammatory reaction related to the carrier state of FMD. The measured acute phase 
response, for all of the included parameters, declined to base-line levels well in advance of 
PID 28, which is the generally accepted time post infection from which carrier status can be 
determined62. 
The second manuscript dealt with the local immune response, through measurements of 
mRNA expression of inflammatory cytokines IFN-α and-β as well as TNF-α in sequentially 
collected biopsy samples from the pharyngeal mucosa of FMD infected cattle. This study was 
based on a slightly different combination of experiments compared to the first manuscript 
(FMD 3C 2008, FMD 5C 2010 and FMD 7C 2010). The carrier-status of individual animals 
had been determined in all of the experiments included. 
Biopsy samples were collected during acute, sub-acute and late phases of infection, with 
relative expression levels of individual targets compared to levels measured in pre-
inoculation samples harvested from each individual animal. Results indicated significantly 
down regulated expression of IFN-β mRNA during acute infection, which is consistent with 
previously published findings from cell-culture based experiments27,28,73. There was also a 
significant difference in the expression levels of TNF-α, with higher levels in carriers 
compared to non-carriers. These findings are also in line with an earlier report77 which was 
based on only a small number of animals. The study design used to investigate variations in 
the relative gene expression levels has been substantially improved during the current project 
when compared to previous investigations. The possibility of analyzing sequentially 
harvested tissue samples from a relatively large number of animals provides further strength 
for this kind of investigation. 
The third manuscript was based on an investigation of FMDV-pathogenesis through 
measurements of FMDV RNA in sequentially collected biopsies of pharyngeal mucosa. The 
experiments included in this analysis were similar to those included in the previous 
manuscript. 
The pharyngeal epithelia has been reported to be an important site for FMDV replication 
during both early6,21,59,75 and persistent75,80 phases of infection. Despite this, the levels of 
FMDV RNA found in biopsy samples collected during the early infection, and in samples of 
the dorsal soft palate and associated lymph nodes harvested post mortem during the late phase 
of infection, were unexpectedly low. The investigation was based on results from two qRT-
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PCR assays, targeting different regions of the FMDV genome. Samples of oropharyngeal 
fluid (probang samples) were analyzed using a similar assay and were found to contain much 
larger amounts of FMDV RNA, than the tissue samples harvested at the  same stage of 
infection.  
The low prevalence of FMDV RNA detected in biopsies and tissue samples could be 
interpreted to indicate that the predominant sites of FMDV replication and persistence are not 
located within the region targeted for sampling. Further experiments will be needed in order 
to fully elucidate the pathogenesis of early and persistent phases of FMDV infection in cattle. 
Analysis of virus excretion in probang samples from the three full-term experiments indicated 
that the overall prevalence of FMDV-carriers amongst infected animals was 44%, which is 
consistent with previous reports2,6,52. An interesting finding from the analysis of probang 
samples was that virus excretion in non-carriers became undetectable at approximately PID 
14, whereas FMDV RNA remained detectable at consistent levels throughout the experiments 
(up to 100 days) in the carriers. 
Previous publications investigating sites of FMDV replication have all been based on the 
analysis of tissue samples collected from euthanized animals. The suitability of using biopsy 
samples of the DSP for this type of investigation could be evaluated through comparisons of 
the levels of FMDV detectable in biopsy samples and larger tissue samples collected post 
mortem. For instance, biopsy samples could be collected from individual animals which 
would subsequently be euthanized for collection of larger tissue samples from the 
corresponding region. 
The apparent advantage of being able to collect biopsy samples from live animals is that it is 
possible to collect sequential samples from individual animals, and also to be able to evaluate 
the early events of infection in animals which could then be followed to determine their 
eventual carrier-status. 
It should be possible to develop the technique of enodscopical sampling of live animals 
further by harvesting biopsies from different anatomical regions. Relevant targets could, for 
example, include epithelia from the lower regions of the respiratory tract.  
In relation to this, it could also be relevant to compare the characteristics of FMDV infection 
in animals which have been exposed to the virus through different routes. There have been 
recent publications investigating the early events of FMDV pathogenesis in animals infected 
through controlled aerosol exposure8,59. It would be reasonable to believe, that there could be 
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some significant variations in the characteristics of the early infection in animals that had 
been infected via more natural routes of exposure, such as direct contact with infected 
animals. 
The carrier status of the animals included in this project has been determined through 
detection of FMDV RNA in probang samples using qRT-PCR. The definition of an FMDV-
carrier is based on the detection of infectious FMDV in oropharyngeal excretions beyond 28 
days post infection. When using qRT-PCR for this analysis, it is not possible to differentiate 
between infectious and non-infectious virus, as can be done through virus isolation in cell 
culture. Virus isolation in cell culture was attempted in the earlier experiments performed 
within the project, but due to technical problems, with an apparent need of optimization of 
the protocol in use, this method was abolished for the current purpose. As the results from 
qRT-PCR analysis of probang samples were very consistent, it was concluded that this 
method was suitable for detection of FMDV-carriers in experimental infections, which has 
also been supported by previous reports76. It would, however, add further strength to the 
investigations if the proposed carrier status of the included animals could be corroborated 
through isolation of infectious virus from probang samples. 
Conclusions and perspectives. 
Through measurements of the acute phase proteins SAA and HP, as well as bioactive type 1 
IFN in sera of FMDV infected cattle, it was concluded that there was no measurable systemic 
inflammatory reaction related to the carrier status of FMD. The three markers could, 
however, be used for detection of a systemic reaction during the early stages of FMDV 
infection in cattle. Preliminary studies also indicated that the magnitude of the acute phase 
response in SAA and HP could be used in combination with observations of clinical signs of 
infection in order to achieve a more objective evaluation of the severity of the clinical 
infection. 
There was an indication of a possible difference in the HP-response in sera from animals that 
developed into FMDV-carriers and those that did not. This finding should be confirmed 
through further investigations. 
There was a measurable down-regulation in expression of IFN-β mRNA in biopsies from the 
DSP harvested during acute infection, which corroborates previous reports from other 
groups27,28,73. 
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TNF-α mRNA levels in DSP biopsies was significantly up-regulated during acute and late 
phases of infection, with significantly higher levels in carriers compared to non-carriers. This 
finding could indicate a prolonged inflammatory reaction in the DSP of FMDV-carriers 
despite the lack of a continued APP response. 
The pathogenesis of FMDV infection in cattle needs further investigations in order for 
consistent conclusions to be made. There is a general lack of consensus between researchers 
regarding the exact events involved in both the early and persistent stages of the infection. 
The results from the investigations included in this project add further uncertainties in 
relation to some of the commonly cited reports within the area. Collaborations between 
groups interested in research within this area, with some harmonization of the methods used 
for investigations would be highly beneficial for future investigations.  
The developed technique of endoscopical collection of tissue samples from live animals can 
be further optimized, and should be highly relevant for future studies of the pathogenesis of 
FMDV-infection. Results of the performed gene expression analysis in biopsy samples 
harvested from the DSP indicate that further development of this technique would be relevant 
for future experiments with aims of investigating the detailed mechanisms involved in the 
host response to FMDV in cattle.  
 
                                                                                Reference list                                                                                                                                                              
 
124 
 
Reference List 
 
 1.  Aggarwal, N., Z. Zhang, S. Cox, R. Statham, S. Alexandersen, R. P. Kitching, 
and P. V. Barnett. 2002. Experimental studies with foot-and-mouth disease virus, 
strain O, responsible for the 2001 epidemic in the United Kingdom. Vaccine 20:2508-
2515. 
 2.  Alexandersen, S. and N. Mowat. 2005. Foot-and-mouth disease: host range and 
pathogenesis. Curr. Top. Microbiol. Immunol. 288:9-42. 
 3.  Alexandersen, S., M. B. Oleksiewicz, and A. I. Donaldson. 2001. The early 
pathogenesis of foot-and-mouth disease in pigs infected by contact: a quantitative 
time-course study using TaqMan RT-PCR. J. Gen. Virol. 82:747-755. 
 4.  Alexandersen, S., M. Quan, C. Murphy, J. Knight, and Z. Zhang. 2003. Studies of 
quantitative parameters of virus excretion and transmission in pigs and cattle 
experimentally infected with foot-and-mouth disease virus. J. Comp Pathol. 129:268-
282. 
 5.  Alexandersen, S., Z. Zhang, and A. I. Donaldson. 2002. Aspects of the persistence 
of foot-and-mouth disease virus in animals--the carrier problem. Microbes. Infect. 
4:1099-1110. 
 6.  Alexandersen, S., Z. Zhang, A. I. Donaldson, and A. J. Garland. 2003. The 
pathogenesis and diagnosis of foot-and-mouth disease. J. Comp Pathol. 129:1-36. 
 7.  Amadori, M., I. L. Archetti, R. Verardi, and C. Berneri. 1995. Role of a distinct 
population of bovine gamma delta T cells in the immune response to viral agents. 
Viral Immunol. 8:81-91. 
 8.  Arzt, J., J. M. Pacheco, and L. L. Rodriguez. 2010. The early pathogenesis of foot-
and-mouth disease in cattle after aerosol inoculation: identification of the 
nasopharynx as the primary site of infection. Vet. Pathol. 47:1048-1063. 
 9.  Balinda, S. N., H. R. Siegismund, V. B. Muwanika, A. K. Sangula, C. Masembe, 
C. Ayebazibwe, P. Normann, and G. J. Belsham. 2010. Phylogenetic analyses of 
the polyprotein coding sequences of serotype O foot-and-mouth disease viruses in 
East Africa: evidence for interserotypic recombination. Virol. J. 7:199. 
 10.  Barnett, P. V., S. J. Cox, N. Aggarwal, H. Gerber, and K. C. McCullough. 2002. 
Further studies on the early protective responses of pigs following immunisation with 
high potency foot and mouth disease vaccine. Vaccine 20:3197-3208. 
 11.  Baumann, H. and J. Gauldie. 1994. The acute phase response. Immunol. Today 
15:74-80. 
 12.  Bautista, E. M., G. S. Ferman, D. Gregg, M. C. Brum, M. J. Grubman, and W. 
T. Golde. 2005. Constitutive expression of alpha interferon by skin dendritic cells 
                                                                                Reference list                                                                                                                                                              
 
125 
 
confers resistance to infection by foot-and-mouth disease virus. J. Virol. 79:4838-
4847. 
 13.  Belsham, G. J. 2005. Translation and replication of FMDV RNA. Curr. Top. 
Microbiol. Immunol. 288:43-70. 
 14.  Belsham, G. J. and J. K. Brangwyn. 1990. A region of the 5' noncoding region of 
foot-and-mouth disease virus RNA directs efficient internal initiation of protein 
synthesis within cells: involvement with the role of L protease in translational control. 
J. Virol. 64:5389-5395. 
 15.  Belsham, G. J., G. M. McInerney, and N. Ross-Smith. 2000. Foot-and-mouth 
disease virus 3C protease induces cleavage of translation initiation factors eIF4A and 
eIF4G within infected cells. J. Virol. 74:272-280. 
 16.  Boehm, U., T. Klamp, M. Groot, and J. C. Howard. 1997. Cellular responses to 
interferon-gamma. Annu. Rev. Immunol. 15:749-795. 
 17.  Brown, C. C., J. Chinsangaram, and M. J. Grubman. 2000. Type I interferon 
production in cattle infected with 2 strains of foot-and-mouth disease virus, as 
determined by in situ hybridization. Can. J. Vet. Res. 64:130-133. 
 18.  Brown, C. C., R. F. Meyer, H. J. Olander, C. House, and C. A. Mebus. 1992. A 
pathogenesis study of foot-and-mouth disease in cattle, using in situ hybridization. 
Can. J. Vet. Res. 56:189-193. 
 19.  Brown, C. C., M. E. Piccone, P. W. Mason, T. S. McKenna, and M. J. Grubman. 
1996. Pathogenesis of wild-type and leaderless foot-and-mouth disease virus in cattle. 
J. Virol. 70:5638-5641. 
 20.  Burrows, R. 1966. Studies on the carrier state of cattle exposed to foot-and-mouth 
disease virus. J. Hyg. (Lond) 64:81-90. 
 21.  Burrows, R., J. A. Mann, A. J. Garland, A. Greig, and D. Goodridge. 1981. The 
pathogenesis of natural and simulated natural foot-and-mouth disease infection in 
cattle. J. Comp Pathol. 91:599-609. 
 22.  Carroll, M. B. 2011. The impact of biologic response modifiers on hepatitis B virus 
infection. Expert. Opin. Biol. Ther. 
 23.  Chinsangaram, J., M. P. Moraes, M. Koster, and M. J. Grubman. 2003. Novel 
viral disease control strategy: adenovirus expressing alpha interferon rapidly protects 
swine from foot-and-mouth disease. J. Virol. 77:1621-1625. 
 24.  Chinsangaram, J., M. E. Piccone, and M. J. Grubman. 1999. Ability of foot-and-
mouth disease virus to form plaques in cell culture is associated with suppression of 
alpha/beta interferon. J. Virol. 73:9891-9898. 
 25.  Condy, J. B., R. S. Hedger, C. Hamblin, and I. T. Barnett. 1985. The duration of 
the foot-and-mouth disease virus carrier state in African buffalo (i) in the individual 
animal and (ii) in a free-living herd. Comp Immunol. Microbiol. Infect. Dis. 8:259-
265. 
                                                                                Reference list                                                                                                                                                              
 
126 
 
 26.  Cox, S. J., P. V. Barnett, P. Dani, and J. S. Salt. 1999. Emergency vaccination of 
sheep against foot-and-mouth disease: protection against disease and reduction in 
contact transmission. Vaccine 17:1858-1868. 
 27.  de Los Santos, T., B. S. de Avila, R. Weiblen, and M. J. Grubman. 2006. The 
leader proteinase of foot-and-mouth disease virus inhibits the induction of beta 
interferon mRNA and blocks the host innate immune response. J. Virol. 80:1906-
1914. 
 28.  de Los Santos, T., F. Diaz-San Segundo, and M. J. Grubman. 2007. Degradation 
of nuclear factor kappa B during foot-and-mouth disease virus infection. J. Virol. 
81:12803-12815.  
 29.  Diebold, S. S. 2009. Activation of dendritic cells by toll-like receptors and C-type 
lectins. Handb. Exp. Pharmacol.3-30. 
 30.  Doel, T. R., L. Williams, and P. V. Barnett. 1994. Emergency vaccination against 
foot-and-mouth disease: rate of development of immunity and its implications for the 
carrier state. Vaccine 12:592-600. 
 31.  Donaldson, A. I. and R. P. Kitching. 1989. Transmission of foot-and-mouth disease 
by vaccinated cattle following natural challenge. Res. Vet. Sci. 46:9-14. 
 32.  Eckersall, P. D. and R. Bell. 2010. Acute phase proteins: Biomarkers of infection 
and inflammation in veterinary medicine. Vet. J. 185:23-27. 
 33.  Godson, D. L., M. Campos, S. K. ttah-Poku, M. J. Redmond, D. M. Cordeiro, M. 
S. Sethi, R. J. Harland, and L. A. Babiuk. 1996. Serum haptoglobin as an indicator 
of the acute phase response in bovine respiratory disease. Vet. Immunol. 
Immunopathol. 51:277-292. 
 34.  Grubman, M. J., M. P. Moraes, S. F. az-San, L. Pena, and S. T. de Los. 2008. 
Evading the host immune response: how foot-and-mouth disease virus has become an 
effective pathogen. FEMS Immunol. Med. Microbiol. 53:8-17. 
 35.  Guzylack-Piriou, L., F. Bergamin, M. Gerber, K. C. McCullough, and A. 
Summerfield. 2006. Plasmacytoid dendritic cell activation by foot-and-mouth disease 
virus requires immune complexes. Eur. J. Immunol. 36:1674-1683. 
 36.  Halasa, T., A. Boklund, S. Cox, and C. Enoe. 2011. Meta-analysis on the efficacy 
of foot-and-mouth disease emergency vaccination. Prev. Vet. Med. 98:1-9. 
 37.  Harwood, L. J., H. Gerber, F. Sobrino, A. Summerfield, and K. C. McCullough. 
2008. Dendritic cell internalization of foot-and-mouth disease virus: influence of 
heparan sulfate binding on virus uptake and induction of the immune response. J. 
Virol. 82:6379-6394. 
 38.  He, X. S. and H. B. Greenberg. 2002. CD8+ T-cell response against hepatitis C 
virus. Viral Immunol. 15:121-131. 
 39.  Heegaard, P. M., D. L. Godson, M. J. Toussaint, K. Tjornehoj, L. E. Larsen, B. 
Viuff, and L. Ronsholt. 2000. The acute phase response of haptoglobin and serum 
                                                                                Reference list                                                                                                                                                              
 
127 
 
amyloid A (SAA) in cattle undergoing experimental infection with bovine respiratory 
syncytial virus. Vet. Immunol. Immunopathol. 77:151-159. 
 40.  Horadagoda, N. U., K. M. Knox, H. A. Gibbs, S. W. Reid, A. Horadagoda, S. E. 
Edwards, and P. D. Eckersall. 1999. Acute phase proteins in cattle: discrimination 
between acute and chronic inflammation. Vet. Rec. 144:437-441. 
 41.  Huard, B. and K. Fruh. 2000. A role for MHC class I down-regulation in NK cell 
lysis of herpes virus-infected cells. Eur. J. Immunol. 30:509-515. 
 42.  Juleff, N., M. Windsor, E. Reid, J. Seago, Z. Zhang, P. Monaghan, I. W. 
Morrison, and B. Charleston. 2008. Foot-and-mouth disease virus persists in the 
light zone of germinal centres. PLoS. One. 3:e3434. 
 43.  Karre, K. 1997. How to recognize a foreign submarine. Immunol. Rev. 155:5-9. 
 44.  Kim, S. Y. and D. H. Solomon. 2010. Tumor necrosis factor blockade and the risk of 
viral infection. Nat. Rev. Rheumatol. 6:165-174. 
 45.  Knowles, N. J. and A. R. Samuel. 2003. Molecular epidemiology of foot-and-mouth 
disease virus. Virus Res. 91:65-80. 
 46.  Le, B. A., N. Etchart, C. Rossmann, M. Ashton, S. Hou, D. Gewert, P. Borrow, 
and D. F. Tough. 2003. Cross-priming of CD8+ T cells stimulated by virus-induced 
type I interferon. Nat. Immunol. 4:1009-1015. 
 47.  Lindahl, P., I. Gresser, P. Leary, and M. Tovey. 1976. Interferon treatment of 
mice: enhanced expression of histocompatibility antigens on lymphoid cells. Proc. 
Natl. Acad. Sci. U. S. A 73:1284-1287. 
 48.  Mason, P. W., M. J. Grubman, and B. Baxt. 2003. Molecular basis of pathogenesis 
of FMDV. Virus Res. 91:9-32. 
 49.  McCullough, K. C., D. Parkinson, and J. R. Crowther. 1988. Opsonization-
enhanced phagocytosis of foot-and-mouth disease virus. Immunology 65:187-191. 
 50.  McVicar, J. W. and P. Sutmoller. 1968. Sheep and goats as foot-and-mouth disease 
carriers. Proc. Annu. Meet. U. S. Anim Health Assoc. 72:400-406. 
 51.  McVicar, J. W. and P. Sutmoller. 1976. Growth of foot-and-mouth disease virus in 
the upper respiratory tract of non-immunized, vaccinated, and recovered cattle after 
intranasal inoculation. J. Hyg. (Lond) 76:467-481. 
 52.  Moonen, P. and R. Schrijver. 2000. Carriers of foot-and-mouth disease virus: a 
review. Vet. Q. 22:193-197. 
 53.  Murphy, K., P. Travers, and M. Walport. 2008. Development and Survival of 
Lymphocytes, p. 257-320. In Kenneth Murphy, Paul Travers, and Mark Walport 
(eds.), Janeway's Immunobiology. Garland Science, New York. 
                                                                                Reference list                                                                                                                                                              
 
128 
 
 54.  Murphy, K., P. Travers, and M. Walport. 2008. Dynamics of Adaptive Immunity, 
p. 421-458. In Kenneth Murphy, Paul Travers, and Mark Walport (eds.), Janeway's 
Immunobiology. Garland Science, New York. 
 55.  Murphy, K., P. Travers, and M. Walport. 2008. Innate Immunity, p. 39-108. In 
Kenneth Murphy, Paul Travers, and Mark Walport (eds.), Janeway's Immunobiology. 
Garland Science, New York. 
 56.  Murphy, K., P. Travers, and M. Walport. 2008. The Humoral Immune Response, 
p. 379-420. In Kenneth Murphy, Paul Travers, and Mark Walport (eds.), Janeway's 
Immunobiology. Garland Science, New York. 
 57.  Murphy, K., P. Travers, and M. Walport. 2008. T-cell Mediated Immunity, p. 323-
377. Janeway's Immunobiology. Garland Science, New York. 
 58.  O'Donnell, V., J. M. Pacheco, D. Gregg, and B. Baxt. 2009. Analysis of foot-and-
mouth disease virus integrin receptor expression in tissues from naive and infected 
cattle. J. Comp Pathol. 141:98-112. 
 59.  Pacheco, J. M., J. Arzt, and L. L. Rodriguez. 2010. Early events in the 
pathogenesis of foot-and-mouth disease in cattle after controlled aerosol exposure. 
Vet. J. 183:46-53. 
 60.  Peterhans, E., C. Bachofen, H. Stalder, and M. Schweizer. 2010. Cytopathic 
bovine viral diarrhea viruses (BVDV): emerging pestiviruses doomed to extinction. 
Vet. Res. 41:44. 
 61.  Petersen, H. H., J. P. Nielsen, and P. M. Heegaard. 2004. Application of acute 
phase protein measurements in veterinary clinical chemistry. Vet. Res. 35:163-187. 
 62.  Salt, J. S. 1993. The carrier state in foot and mouth disease--an immunological 
review. Br. Vet. J. 149:207-223. 
 63.  Sanz-Parra, A., F. Sobrino, and V. Ley. 1998. Infection with foot-and-mouth 
disease virus results in a rapid reduction of MHC class I surface expression. J. Gen. 
Virol. 79 ( Pt 3):433-436. 
 64.  Stark, G. R., I. M. Kerr, B. R. Williams, R. H. Silverman, and R. D. Schreiber. 
1998. How cells respond to interferons. Annu. Rev. Biochem. 67:227-264. 
 65.  Stetson, D. B. and R. Medzhitov. 2006. Type I interferons in host defense. 
Immunity. 25:373-381. 
 66.  Straver, P. J., P. H. Bool, A. M. Claessens, and J. G. van Bekkum. 1970. Some 
properties of carrier strains of foot-and-mouth disease virus. Arch. Gesamte 
Virusforsch. 29:113-126. 
 67.  Summerfield, A., L. Guzylack-Piriou, L. Harwood, and K. C. McCullough. 2009. 
Innate immune responses against foot-and-mouth disease virus: current understanding 
and future directions. Vet. Immunol. Immunopathol. 128:205-210. 
                                                                                Reference list                                                                                                                                                              
 
129 
 
 68.  Sutmoller, P. and A. Gaggero. 1965. Foot-and mouth diseases carriers. Vet. Rec. 
77:968-969. 
 69.  Takamatsu, H. H., M. S. Denyer, C. Stirling, S. Cox, N. Aggarwal, P. Dash, T. E. 
Wileman, and P. V. Barnett. 2006. Porcine gammadelta T cells: possible roles on 
the innate and adaptive immune responses following virus infection. Vet. Immunol. 
Immunopathol. 112:49-61. 
 70.  Tjornehoj, K., Elsohaby, I, Ayebazibwe, C., Mwiine, F. N., Stenfeldt, C, Sangula, 
A. K., Balinda, S. N., and Alexandersen, S. Use of Priocheck FMDV-NS ELISA 
and Priocheck FMDV type O ELISA in Uganda. EU-FMD open session Vienna 2010 
. 29-9-2010. Ref Type: Abstract 
 71.  Toka, F. N., C. K. Nfon, H. Dawson, D. M. Estes, and W. T. Golde. 2009. 
Activation of porcine natural killer cells and lysis of foot-and-mouth disease virus 
infected cells. J. Interferon Cytokine Res. 29:179-192. 
 72.  Vilcek, J. 2006. Fifty years of interferon research: aiming at a moving target. 
Immunity. 25:343-348. 
 73.  Wang, D., L. Fang, R. Luo, R. Ye, Y. Fang, L. Xie, H. Chen, and S. Xiao. 2010. 
Foot-and-mouth disease virus leader proteinase inhibits dsRNA-induced type I 
interferon transcription by degradation of interferon regulatory factor 3/7. Biochem. 
Biophys. Res. Commun. 
 74.  Yao, Q., Q. Huang, Y. Cao, P. Qian, and H. Chen. 2008. Porcine interferon-gamma 
protects swine from foot-and-mouth disease virus (FMDV). Vet. Immunol. 
Immunopathol. 122:309-311. 
 75.  Zhang, Z. and S. Alexandersen. 2004. Quantitative analysis of foot-and-mouth 
disease virus RNA loads in bovine tissues: implications for the site of viral 
persistence. J. Gen. Virol. 85:2567-2575. 
 76.  Zhang, Z. and S. Alexandersen. 2003. Detection of carrier cattle and sheep 
persistently infected with foot-and-mouth disease virus by a rapid real-time RT-PCR 
assay. J. Virol. Methods 111:95-100. 
 77.  Zhang, Z., J. B. Bashiruddin, C. Doel, J. Horsington, S. Durand, and S. 
Alexandersen. 2006. Cytokine and Toll-like receptor mRNAs in the nasal-associated 
lymphoid tissues of cattle during foot-and-mouth disease virus infection. J. Comp 
Pathol. 134:56-62. 
 78.  Zhang, Z., C. Murphy, M. Quan, J. Knight, and S. Alexandersen. 2004. Extent of 
reduction of foot-and-mouth disease virus RNA load in oesophageal-pharyngeal fluid 
after peak levels may be a critical determinant of virus persistence in infected cattle. J. 
Gen. Virol. 85:415-421. 
 79.  Zhang, Z. D., G. Hutching, P. Kitching, and S. Alexandersen. 2002. The effects of 
gamma interferon on replication of foot-and-mouth disease virus in persistently 
infected bovine cells. Arch. Virol. 147:2157-2167. 
                                                                                Reference list                                                                                                                                                              
 
130 
 
 80.  Zhang, Z. D. and R. P. Kitching. 2001. The localization of persistent foot and mouth 
disease virus in the epithelial cells of the soft palate and pharynx. J. Comp Pathol. 
124:89-94. 
 81.  Zheng, Z. M. 2010. Viral oncogenes, noncoding RNAs, and RNA splicing in human 
tumor viruses. Int. J. Biol. Sci. 6:730-755. 
 
 
 
 
Appendix 1. 
 
131 
 
Appendix I 
Detection of FMDV non-structural protein 3A in frozen tissue sections by 
indirect immunoflourescence. 
Introduction and methods 
Detection of FMDV antigens in frozen tissue sections by indirect immunofluorescence was 
performed using a protocol obtained from IAH-Pirbright 
1
. 
Biopsy samples of pharyngeal mucosa (see manuscript number 2), as well as samples from 
the dorsal soft palate and mandibular and retropharyngeal lymphnodes, collected post 
mortem, were analyzed for the presence of both structural and non-structural FMDV proteins. 
Murine Mab 2C2
2
, raised against nonstructural protein 3A was kindly provided by Emiliana 
Brocchi, Instituto Zooprofilactico Sperimentale della Lombardia, Italy. Mab IB11
1
 raised 
against 146 S FMDV type O antigen was supplied by Nick Juleff, IAH-Pirbright as 
cellculture supernatant, which was subsequently purified using HiTrap protein G columns 
(GE Healthcare, Hillerød, Denmark). 
Tissue samples were frozen in OCT medium (Tissue-Tek) on dry-ice directly after 
harvesting, and were subsequently stored at -70
o
C until further processing. Cryo-embedded 
tissue samples were sectioned and mounted on microscope slides (Superfrost*, Thermo 
Scientific) and left to dry at room-temperature prior to fixation in acetone. Hydrophobic and 
electrostatic forces were blocked through incubation with 5% heat inactivated normal goat 
serum in PBS. Sections were incubated with primary Mabs (diluted 1:1000 in 5% goat 
serum/PBS) for 30 minutes, before washing and incubation with secondary antibodies (Alexa 
fluor range, Invitrogen) for another 30 minutes. Nuclear staining was performed with DAPI 
(Invitrogen, 1:20000 dilution), and slides were mounted using Prolong Gold fluorescence 
mounting medium (Invitrogen). Following overnight incubation, sections were analyzed 
using an Olympus BX 51 Fluorescence microscope in combination with Acell
©
 imaging 
software. 
Results 
Initial results from staining with the Mab 2C2, which recognizes non-structural protein 3A, 
showed a consistent and specific pattern of intra-cellular staining in sections of the 
mandibular lymph nodes from infected animals (see Figures I-1 and I-2) This distinct staining 
pattern was not found in samples harvested from other organs, nor in corresponding samples 
from un-infected animals or isotype-control sections (incubated with non-specific murine 
IgG, Dako). There was, however, a significant amount of unspecific background staining, and 
due to lack of time, further optimization of this method was not achieved. 
Staining with the anti-structural protein Mab IB11 showed non-specific binding, in both test- 
and control sections. Similar results were observed through staining with anti DC-cell marker 
CNA.42 (Dako) and anti-CD8 T cell marker HB 264-15 (kindly provided by Jens Nielsen, 
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DTU-Vet, Lindholm). Due to practical circumstances, further optimization of these methods 
was not attempted. 
Conclusion 
Initial results indicated a distinct intra-cellular staining pattern with the anti-FMDV 3A Mab 
2C2 in the mandibular lympnodes harvested from cattle previously infected with FMDV, 
during both the early (results not shown) and late (PID< 28) stages of infection. The specific 
pattern of staining was found both in animals that were identified as FMDV carriers and in 
those that did not continue to excrete FMDV in oropharyngeal fluid. These findings will 
require further investigations, including optimization of the protocol used in order to reduce 
non-specific background staining, in order for any conclusions to be made.  
Further optimization should also be performed in order to achieve reliable results from 
staining with the Mab IB11 (which recognizes structural proteins), as well as additional 
cellular markers (DC, T-cell sub-populations). Staining with the 2C2 should be combined 
with staining for cellular markers in order to determine the exact localization of binding sites 
within the lymphoid tissue. Furthermore, the procedure for nuclear staining with DAPI 
should be optimized in order to obtain a clearer view of the intracellular localization of the 
specific staining. 
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Figure I-1. Immunofluorescence for FMDV non-structural protein 3A. Mandibular lymph 
node harvested at PID 35 from calf identified as FMDV-carrier. A) staining with Mab 2C2 
shows distinct intracellular pattern. B) parallel control-section incubated with non-specific 
isotype control (murine IgG, DAKO) without the specific pattern of staining. 
B 
A 
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Figure I-2. Immunofluorescence for FMDV non-structural protein 3A. Mandibular lymph 
node harvested at PID 35 from calf identified as non-carrier. A) staining with Mab 2C2 
shows distinct intracellular pattern. B) parallel control-section incubated with non-specific 
isotype control (murine IgG, DAKO) without the specific pattern of staining. 
 
 
 
Figure I-3. Immunofluorescence for FMDV non-structural protein 3A. Retropharyngeal 
lymphnode harvested at PID 35 from 2 different calves detected as FMDV-carrier (A) and 
non-carrier (B) respectively. The sections from the retropharyngeal lymphnodes do not show 
similar staining as seen in the Mandibular lymphnodes in the figures above. 
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